var title_f32_48_33536="Prednisolone: Drug information";
var content_f32_48_33536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisolone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30723?source=see_link\">",
"       Prednisolone (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40376?source=see_link\">",
"       Prednisolone (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9808 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-220.255.2.106-317DDF55DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33536=[""].join("\n");
var outline_f32_48_33536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30723?source=related_link\">",
"      Prednisolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40376?source=related_link\">",
"      Prednisolone (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_48_33537="Giardia trophozoite";
var content_f32_48_33537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giardia trophozoite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power microscopy revealing Giardia trophozoite with easily identified flagella.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jack D Sobel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33537=[""].join("\n");
var outline_f32_48_33537=null;
var title_f32_48_33538="Computed tomography - Tuberculous lymphadenopathy";
var content_f32_48_33538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography - Tuberculous lymphadenopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of neck showing large right supraclavicular node with central hypodensity and rim contrast enhancement (arrow). Typical appearance of tuberculous lymphadenopathy in HIV infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Maartens, MBChB, MMed.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33538=[""].join("\n");
var outline_f32_48_33538=null;
var title_f32_48_33539="Active shoulder abduction against resistance";
var content_f32_48_33539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Active shoulder abduction against resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 553px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold a dumbbell using a \"full can\" position. Then, over a 2 second count, gradually lift your arms in the plane of the scapula, keeping the elbows straight, until your arms are parallel to the ground. Hold for a second, and then slowly lower your arms to the starting position over a 4 second count.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33539=[""].join("\n");
var outline_f32_48_33539=null;
var title_f32_48_33540="Vulvar psoriasis";
var content_f32_48_33540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33540=[""].join("\n");
var outline_f32_48_33540=null;
var title_f32_48_33541="Lichen sclerosus on the wrists in dark skin";
var content_f32_48_33541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple hyperpigmented and hypopigmented papules are present on the ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33541=[""].join("\n");
var outline_f32_48_33541=null;
var title_f32_48_33542="BL bone marrow aspirate smear";
var content_f32_48_33542=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Burkitt lymphoma cells in bone marrow aspirate smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cells have basophilic cytoplasm, round nuclei with coarse chromatin, multiple nucleoli, and numerous cytoplasmic vacuoles. Wright-Giemsa stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ioachim HL, Medeiros LJ. Burkitt lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33542=[""].join("\n");
var outline_f32_48_33542=null;
var title_f32_48_33543="Paraphimosis reduction";
var content_f32_48_33543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paraphimosis reduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Matthew Tews, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33543/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/48/33543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis occurs when the foreskin in the uncircumcised or partially circumcised male is retracted behind the glans penis and cannot be returned to its normal position (",
"    <a class=\"graphic graphic_picture graphicRef76100 \" href=\"mobipreview.htm?22/33/23057\">",
"     picture 1",
"    </a>",
"    ). This urologic emergency impedes blood flow to the glans penis with potential for permanent damage and gangrene.",
"   </p>",
"   <p>",
"    The primary management of paraphimosis consists of timely reduction of the foreskin back over the glans penis and requires appropriate pain control, adjuncts to reduce swelling, and judicious selection of reduction technique. The chosen method depends upon the resources that are available, the degree of penile ischemia present, and the experience of the practitioner. No randomized trials compare the various techniques used for paraphimosis reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/1\">",
"     1",
"    </a>",
"    ]. Successful reduction has been described in case reports or case series with each of the methods discussed below (",
"    <a class=\"graphic graphic_table graphicRef56148 \" href=\"mobipreview.htm?0/46/748\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66864 \" href=\"mobipreview.htm?10/45/10971\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The definition, pathophysiology, and clinical manifestations of paraphimosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penis in the uncircumcised male consists of the penile shaft, glans penis with the coronal sulcus (rim of the glans), and the foreskin (",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"mobipreview.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis is caused by foreskin entrapment behind the coronal sulcus (",
"    <a class=\"graphic graphic_picture graphicRef76100 \" href=\"mobipreview.htm?22/33/23057\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76391 \" href=\"mobipreview.htm?19/0/19462\">",
"     figure 1",
"    </a>",
"    ). Impairment of lymphatic and venous flow from the constricting ring of foreskin causes venous engorgement of the glans penis with swelling. Ultimately, arterial flow to the glans penis becomes compromised over a period of hours to days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Bulbar, urethral, and pudendal vessels may be sequentially impaired. If paraphimosis is not corrected in a timely fashion, penile necrosis, infarction of the glans, or gangrene can occur, followed by autoamputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis reduction is indicated as soon as paraphimosis is identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraphimosis only occurs in the uncircumcised or partially circumcised male. The practitioner should ensure that the penile swelling is due to paraphimosis and not an alternative condition, such as angioedema, insect bite, or constricting band (eg, hair tourniquet). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link&amp;anchor=H10#H10\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful inspection of the penis should occur to ensure that there are no constricting bands or foreign bodies, such as piercing studs, present prior to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patient counseling/Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The boy or man with paraphimosis is typically anxious and in significant pain. The patient and family should receive an explanation of the problem and the planned approach. Anxiety usually recedes once pain is adequately controlled. A child life specialist or other personnel may help with distraction in children while initial adjuncts aimed at reducing swelling and pain are employed. Successful reduction in young boys may require parenteral analgesia and sedation. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuncts'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the benefit of any of the paraphimosis reduction procedures outweighs the risk. The adverse effects of the technique should be disclosed prior to the initiation of the procedure based on the planned approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manual manipulation or paraphimosis reduction with Adson or Babcock clamps may result in minor bruising and superficial abrasions.",
"     </li>",
"     <li>",
"      Reduction procedures involving needle puncture or incision may cause bleeding or infection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"       Hyaluronidase",
"      </a>",
"      injection has been associated with contusion, allergic reaction, and hypotension.",
"     </li>",
"     <li>",
"      Injury to the foreskin during manipulation may lead to scarring and phimosis. Ultimately, circumcision may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most instances, manual manipulation will suffice. However, it is best for the clinician to assemble all equipment they plan to use, including materials needed for invasive reduction should minimally invasive reduction fail. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Invasive reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Minimally invasive reduction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latex-free gloves",
"     </li>",
"     <li>",
"      Topical local anesthetic agent (2 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      gel or EMLA cream: 2.5 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"       prilocaine",
"      </a>",
"      and 2.5 percent lidocaine) OR 1 percent lidocaine without epinephrine for injection",
"     </li>",
"     <li>",
"      25 gauge or smaller (eg, 27 gauge) needle and 3 to 5 mL syringe for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      injection",
"     </li>",
"     <li>",
"      Sterile gauze",
"     </li>",
"     <li>",
"      Adjuncts to reduce swelling: ice, compression dressing (elastic bandage or 2 X 2 inch Kerlix&reg; wrap), or granulated sugar",
"     </li>",
"     <li>",
"      Latex-free surgical glove or condom for application of topical anesthetic, ice,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      granulated sugar",
"     </li>",
"     <li>",
"      Water soluble lubricant",
"     </li>",
"     <li>",
"      Babcock or Adson forceps (",
"      <a class=\"graphic graphic_figure graphicRef77663 \" href=\"mobipreview.htm?21/42/22191\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Invasive reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The equipment may vary depending on the invasive technique chosen. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Invasive reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sterile surgical gloves",
"     </li>",
"     <li>",
"      Betadine&trade; or other antiseptic solution",
"     </li>",
"     <li>",
"      Sterile gauze",
"     </li>",
"     <li>",
"      Sterile surgical towels",
"     </li>",
"     <li>",
"      25 gauge or smaller (eg, 27 gauge) needle (puncture or \"Dundee\" technique)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"       Hyaluronidase",
"      </a>",
"      : 1 mL of 150",
"      <span class=\"nowrap\">",
"       U/mL,",
"      </span>",
"      Wydase&trade; (hyaluronidase injection technique)",
"     </li>",
"     <li>",
"      20 gauge needle and 10 mL syringe (needle aspiration of the glans penis)",
"     </li>",
"     <li>",
"      Scalpel (dorsal slit procedure)",
"     </li>",
"     <li>",
"      Suture material: 3-0 Vicryl Rapide&trade; or similar (dorsal slit procedure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef56148 \" href=\"mobipreview.htm?0/46/748\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66864 \" href=\"mobipreview.htm?10/45/10971\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practitioner should start with the least invasive technique and advance to more invasive techniques only if reduction is unsuccessful. Patients with evidence of significant glans penis ischemia with necrosis require emergent involvement of an urologist. These patients warrant procedural sedation or general anesthesia followed by immediate reduction utilizing invasive techniques (",
"    <a class=\"graphic graphic_table graphicRef56148 \" href=\"mobipreview.htm?0/46/748\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients are exquisitely tender to digital manipulation of the glans penis and foreskin. It is imperative to provide analgesia before attempting reduction of the paraphimosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/7\">",
"     7",
"    </a>",
"    ]. Degree of analgesia necessary is patient dependent and tends to be inversely related to age; adolescents and adults may tolerate application of topical medications or injection of local anesthetic while young boys often require parenteral administration of opioids and sedative agents in addition to local anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .) Adjuncts such as ice, compression, or use of an osmotic agent are often applied after topical anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Topical medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commonly used medications include 2 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    gel or EMLA cream (2.5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    and 2.5 percent lidocaine) applied directly to the skin in the following way [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After spreading the topical agent over the swollen foreskin and glans, the area is covered with the cut-off fingertip of a disposable glove or an occlusive dressing to keep the medication in place [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alternatively, a 4x4 gauze bandage impregnated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ointment (up to 5 percent) may be wrapped around the penis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Onset of anesthesia can take several minutes to an hour. The effectiveness of the medication should be determined before attempting reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/8\">",
"     8",
"    </a>",
"    ]. These medicines should not be used in infants under three months of age or in patients with predisposition for methemoglobinemia, such as glucose 6 phosphate dehydrogenase deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Local anesthesia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Local infiltration",
"      </strong>",
"      &mdash; The use of epinephrine may cause further penile ischemia through vasoconstriction of the penile arteries and is contraindicated when infiltrating the penis. Local infiltration with one percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine (maximum dose: 4",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or with 0.25 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      (maximum dose: 2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      can be used before attempting paraphimosis reduction with Adson forceps. This approach complements procedural sedation or may be used alone in the older cooperative patient. The foreskin is anesthetized either in the 12 o'clock position when grasping with a single Adson forceps, or in the 9 and 3 o'clock position when two forceps are applied (",
"      <a class=\"graphic graphic_figure graphicRef77663 \" href=\"mobipreview.htm?21/42/22191\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/10\">",
"       10",
"      </a>",
"      ]. The indications, contraindications, and toxicity of infiltrative anesthetics are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H25\">",
"       'Traction with forceps'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Dorsal penile nerve block",
"      </strong>",
"      &mdash; This technique provides full regional anesthesia to the penis for all paraphimosis reduction methods, but is more invasive and has greater potential for morbidity than the other local techniques. The procedure is described separately (",
"      <a class=\"graphic graphic_figure graphicRef79052 \" href=\"mobipreview.htm?31/12/31938\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30100?source=see_link&amp;anchor=H2311462#H2311462\">",
"       \"Management of zipper injuries\", section on 'Dorsal penile block'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Opioid analgesia and procedural sedation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Opioid analgesia",
"      </strong>",
"      &mdash; Oral medications (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      , hydrocodone) are typically inadequate as sole measures to control the pain of paraphimosis reduction. However, they can be used in conjunction with adjuncts and topical analgesia. Should a reduction need to be carried out in a more rapid fashion, parenteral opioids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      ), with or without procedural sedation, may be administered. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjuncts'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Topical medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Procedural sedation",
"      </strong>",
"      &mdash; The increased use of medications like",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      that have amnestic and analgesic properties with lesser potential for respiratory depression has enabled management of sedation and analgesia outside the operating room. A large margin of safety for emergent sedation requires restriction of this procedure to patients without significant airway concerns or serious systemic disease, close attention to the patient using noninvasive monitoring, and sedation personnel present during the procedure who are not directly involved in the reduction attempts. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     General anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;General anesthesia has previously been recommended as best for reduction of paraphimosis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/12\">",
"     12",
"    </a>",
"    ]. However, this approach requires the emergent availability of urology, anesthesiology, and operating room personnel. With advances in the use of procedural sedation in the emergency department, general anesthesia is now reserved for recalcitrant cases or cases with significant ischemia not amenable to bedside reduction procedures or requiring immediate reconstructive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adjuncts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive techniques combined with pain control should be used to facilitate reduction of the foreskin in patients without signs of significant glans penis ischemia with necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/3\">",
"     3",
"    </a>",
"    ]. The noninvasive techniques can be time consuming, but with patience, are rewarding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Ice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ice can aid in the manual reduction of paraphimosis as long as signs of ischemia or necrosis are not present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anesthetic jelly (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      gel) is placed on the penis to lubricate and anesthetize the area. Ice is placed in a rubber glove which is tied off at the end so the ice and water remain in the glove. The thumb of the glove is placed over the penis and invaginated into the glove to surround the penis with ice.",
"     </li>",
"     <li>",
"      Alternately, the penis can be wrapped in plastic or the tip of a glove to provide compression followed by placement of ice over the swollen foreskin and glans. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Manual compression and reduction'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Ace or Kerlix bandage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the swollen glans and foreskin is commonly done by a gloved hand but can also be facilitated by a 2 x 2 inch Kerlix&reg; bandage or an Ace&reg; wrap. Wrapping should start distally and progress proximally. Approximately five to seven minutes of pressure facilitates fluid movement through the constricting foreskin to reduce glans swelling prior to manual reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Manual compression and reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Osmotic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique applies the physiologic principle that fluid flows down its concentration gradient, in this case from the hypotonic fluid in the penis to the hypertonic agent placed on the skin. The most common osmotic agent used in the literature is fine granulated sugar because salt is more irritating. This technique has also been applied successfully to other conditions such as rectal prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granulated sugar is placed on the swollen glans penis and foreskin. The penis is then covered with the finger of a rubber glove or a condom and observed for reduction which may require several hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/15\">",
"     15",
"    </a>",
"    ]. This method requires patience and should not be used if emergency reduction is needed in the face of ischemic changes of the glans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Minimally invasive reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach and tips for paraphimosis reduction are described in the tables (",
"    <a class=\"graphic graphic_table graphicRef56148 \" href=\"mobipreview.htm?0/46/748\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66864 \" href=\"mobipreview.htm?10/45/10971\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/3,16\">",
"     3,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Manual compression and reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ice and topical anesthesia are usually applied prior to manual reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. Parenteral pain control and sedation are often needed, as well. The distal penis is grasped with a gloved hand and squeezed circumferentially for several minutes until the swelling has subsided enough to reduce the foreskin over the glans (",
"    <a class=\"graphic graphic_figure graphicRef57700 \" href=\"mobipreview.htm?5/56/6016\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Once compression is complete and after generous application of water soluble lubricant, the foreskin is peeled over the glans using forefingers and middle fingers placed behind the swollen foreskin on either side while simultaneously pushing with thumbs located on the glans penis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/3\">",
"     3",
"    </a>",
"    ]. As the glans is pressed through the foreskin opening, the forefingers pull and reduce the constricted foreskin over the glans penis (",
"    <a class=\"graphic graphic_figure graphicRef57700 \" href=\"mobipreview.htm?5/56/6016\">",
"     figure 4",
"    </a>",
"    ). This technique is successful in the majority of boys with paraphimosis. Young boys typically require procedural sedation to tolerate manual reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Traction with forceps",
"    </span>",
"    &nbsp;&mdash;&nbsp;If manual reduction fails, paraphimosis reduction may be attempted using blunt Babcock forceps or sharp Adson forceps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/16\">",
"     16",
"    </a>",
"    ]. In either case, adequate measures must be taken to ensure patient cooperation and comfort. Young boys typically require procedural sedation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Babcock forceps",
"      </strong>",
"      &ndash; Non-crushing Babcock forceps can be placed in each of four quadrants of the swollen foreskin, followed by continuous, gentle, symmetrical traction until reduction of the foreskin has occurred (",
"      <a class=\"graphic graphic_figure graphicRef77663 \" href=\"mobipreview.htm?21/42/22191\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Adson forceps",
"      </strong>",
"      &ndash; Topical analgesia using EMLA applied for 45 to 60 minutes held in place with an occlusive dressing or local injection of one percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine at the site of sharp Adson forceps application complements procedural sedation, although local analgesia alone may suffice for older boys and adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/16\">",
"       16",
"      </a>",
"      ]. One tine of the Adson forceps is placed under the constricting band and one on the superficial skin. A secure grasp is obtained and constant, steady traction is applied distally until reduction of the band over the glans occurs. This can be modified by using two forceps at the nine and three o'clock positions (",
"      <a class=\"graphic graphic_figure graphicRef77663 \" href=\"mobipreview.htm?21/42/22191\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Invasive reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;These techniques are usually performed by a urologist, but can also be performed by a knowledgeable clinician if no urologist is available and emergent reduction is necessary (",
"    <a class=\"graphic graphic_table graphicRef56148 \" href=\"mobipreview.htm?0/46/748\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66864 \" href=\"mobipreview.htm?10/45/10971\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Puncture technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The puncture technique (the Dundee technique) may be used after failed attempts at reduction using minimally invasive methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/2,17-21\">",
"     2,17-21",
"    </a>",
"    ]. After appropriate local analgesia and sedation as needed, the patient is prepped with antiseptic solution. Multiple punctures are then made in the edematous foreskin using a 25 gauge or smaller needle (",
"    <a class=\"graphic graphic_figure graphicRef65267 \" href=\"mobipreview.htm?3/32/3598\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/2,22\">",
"     2,22",
"    </a>",
"    ]. Subsequently, the foreskin is reduced using manual compression and reduction (",
"    <a class=\"graphic graphic_figure graphicRef57700 \" href=\"mobipreview.htm?5/56/6016\">",
"     figure 4",
"    </a>",
"    ). Previous reports have described successful reduction even after prolonged paraphimosis lasting up to 168 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/2\">",
"     2",
"    </a>",
"    ]. In some instances of delayed reduction of paraphimosis, a fibrotic band forms, and incision of the band is still necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Dorsal slit procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"     Hyaluronidase",
"    </a>",
"    , a natural protein that causes hydrolysis of hyaluronic acid, an extracellular mucopolysaccharide, may be used to augment the efficacy of the multiple puncture technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. When injected using a tuberculin syringe into one or more sites of the edematous foreskin as 1 mL of 150",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    (Wydase&trade;), hyaluronidase causes a rapid decrease in preputial swelling that allows manual reduction to proceed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"     Hyaluronidase",
"    </a>",
"    is contraindicated in the presence of cancer or infection because spread of bacteria or malignant cells may result. Adverse effects are uncommon and include ecchymosis, anaphylaxis, shock, and hypovolemia, especially if inadvertent intravascular injection occurs. Hyaluronidase may have limited availability in some health care settings and is not typically required for the puncture method to be successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Glans penis aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of the glans penis is another invasive method of reduction that may be utilized if minimally invasive techniques fail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/25\">",
"     25",
"    </a>",
"    ]. After performing a penile block, the clinician applies a tourniquet to the penile shaft proximal to the paraphimotic foreskin. The glans penis is prepped sterilely, and a 20 gauge needle, attached to a 10 mL syringe, is inserted into the glans penis parallel to the urethra (",
"    <a class=\"graphic graphic_figure graphicRef55492 \" href=\"mobipreview.htm?16/21/16734\">",
"     figure 6",
"    </a>",
"    ). Approximately 3 to 10 mL of blood are aspirated resulting in marked shrinkage of the glans penis. The needle is removed and a firm, squeezing pressure to the glans is applied, just as in manual reduction. While holding this pressure, the tourniquet is released, and the constricted foreskin is reduced over the shrunken glans. Without the tourniquet, the glans will rapidly refill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Dorsal slit procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incision of the constricting band of foreskin in paraphimosis is sometimes necessary if other techniques fail. This procedure is usually performed by a urologist, but can be performed by an experienced clinician at the bedside with procedural sedation if there is no urologist available. A dorsal penile block may be employed for local anesthesia in conjunction with procedural sedation. The penis and foreskin are prepped in sterile fashion using liberal amounts of antiseptic solution (eg, Betadine&trade;) and sterile drapes. Two methods have been described for the dorsal slit procedure (",
"    <a class=\"graphic graphic_figure graphicRef61427 \" href=\"mobipreview.htm?40/31/41458\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An incision is made along the dorsal skin longitudinally for a length of 1 to 2 cm over the constriction. This will allow edema to flow past the constricting ring and decrease glans edema so that the foreskin can be returned to its normal position. Following reduction, sutures are placed transversely and perpendicular to the longitudinal incision with 4-0 rapidly absorbing suture (eg, 4-0 chromic or similar suture) (",
"      <a class=\"graphic graphic_figure graphicRef61427 \" href=\"mobipreview.htm?40/31/41458\">",
"       figure 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alternatively, two hemostats are inserted in the 12 o'clock position in order to crush the skin to decrease the blood supply. After one minute, an incision is made through the skin between the two hemostats, and the foreskin is reduced. Before removing the hemostats, the two edges are closed with a rapidly absorbing suture (eg, 4-0 chromic or similar suture) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33543/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who require a dorsal slit procedure for paraphimosis reduction undergo delayed circumcision after full resolution of foreskin edema. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Follow-up care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the benefit of any of the paraphimosis reduction procedures outweighs the risk of ischemia to the penis. The adverse effects depend on the technique.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manual manipulation or paraphimosis reduction with Adson or Babcock clamps may result in minor bruising and abrasion to the foreskin and glans penis.",
"     </li>",
"     <li>",
"      Reduction procedures involving needle puncture or dorsal slit incision may cause bleeding or infection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"       Hyaluronidase",
"      </a>",
"      injection has been associated with contusion, allergic reaction, and hypotension.",
"     </li>",
"     <li>",
"      Injury to the foreskin during manipulation may lead to scarring and phimosis. Ultimately, circumcision may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful reduction of the paraphimosis by minimally invasive techniques, the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parent should receive local care instructions that will reestablish physiologic function of the foreskin and help prevent future occurrences. These instructions consist of reinforcement of proper hygiene, avoidance of forced retraction of the foreskin in the young boy, and avoidance of irritants.",
"   </p>",
"   <p>",
"    Trauma to the foreskin during paraphimosis reduction may lead to phimosis. For this reason, many advocate referral of all patients to a urologist after paraphimosis reduction to determine the need for circumcision. In addition, patients who have a repeated episode of paraphimosis warrant referral for circumcision.",
"   </p>",
"   <p>",
"    In patients for whom paraphimosis reduction is uneventful, circumcision may not be necessary and follow-up may occur with the primary care provider in one to two weeks in order to evaluate for secondary infection and to reinforce proper hygiene.",
"   </p>",
"   <p>",
"    Adolescents and adults who sustain paraphimosis secondary to body piercing apparatus should be instructed not to reinsert these foreign bodies. Those who sustain paraphimosis following intercourse should be cautioned to refrain from sexual activities for several days.",
"   </p>",
"   <p>",
"    Follow-up evaluation with a urologist is indicated for all patients who have undergone paraphimosis reduction by invasive methods. Elective circumcision is typically recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraphimosis occurs when the foreskin in the uncircumcised or partially circumcised male is retracted behind the glans penis and cannot be returned to its normal position (",
"      <a class=\"graphic graphic_picture graphicRef76100 \" href=\"mobipreview.htm?22/33/23057\">",
"       picture 1",
"      </a>",
"      ). Impairment of lymphatic and venous flow from the constricting ring of foreskin causes venous engorgement of the glans penis with swelling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paraphimosis reduction is indicated as soon as paraphimosis is identified. The practitioner should ensure that the penile swelling is due to paraphimosis and not an alternative condition, such as angioedema, insect bite, or constricting band (eg, hair tourniquet). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link&amp;anchor=H10#H10\">",
"       \"Paraphimosis: Definition, pathophysiology, and clinical features\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with paraphimosis are exquisitely tender to digital manipulation of the glans penis and foreskin. It is imperative to provide analgesia or local anesthesia (",
"      <a class=\"graphic graphic_figure graphicRef79052 \" href=\"mobipreview.htm?31/12/31938\">",
"       figure 3",
"      </a>",
"      ) before attempting reduction. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Analgesia and sedation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Local anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive techniques combined with pain control should be used to facilitate reduction of the foreskin in patients without signs of significant glans penis ischemia or necrosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjuncts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The practitioner should start with the least invasive technique and advance to more invasive techniques only if reduction is unsuccessful (",
"      <a class=\"graphic graphic_figure graphicRef57700 \" href=\"mobipreview.htm?5/56/6016\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77663 \" href=\"mobipreview.htm?21/42/22191\">",
"       figure 2",
"      </a>",
"      ). The procedure summary (",
"      <a class=\"graphic graphic_table graphicRef56148 \" href=\"mobipreview.htm?0/46/748\">",
"       table 1",
"      </a>",
"      ) and tips (",
"      <a class=\"graphic graphic_table graphicRef66864 \" href=\"mobipreview.htm?10/45/10971\">",
"       table 2",
"      </a>",
"      ) are provided in the tables. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Minimally invasive reduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Invasive reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are not reduced with minimally invasive methods or who have evidence of significant glans penis ischemia with necrosis warrant emergent involvement of a urologist. These patients typically require procedural sedation or general anesthesia followed by immediate reduction utilizing invasive techniques (",
"      <a class=\"graphic graphic_figure graphicRef65267 \" href=\"mobipreview.htm?3/32/3598\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55492 \" href=\"mobipreview.htm?16/21/16734\">",
"       figure 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef61427 \" href=\"mobipreview.htm?40/31/41458\">",
"       figure 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Invasive reduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/1\">",
"      Mackway-Jones K, Teece S. Best evidence topic reports. Ice, pins, or sugar to reduce paraphimosis. Emerg Med J 2004; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/2\">",
"      Reynard JM, Barua JM. Reduction of paraphimosis the simple way - the Dundee technique. BJU Int 1999; 83:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/3\">",
"      Dubin J, Davis JE. Penile emergencies. Emerg Med Clin North Am 2011; 29:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/4\">",
"      McCollough M, Sharieff GQ. Abdominal surgical emergencies in infants and young children. Emerg Med Clin North Am 2003; 21:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/5\">",
"      Hollowood AD, Sibley GN. Non-painful paraphimosis causing partial amputation. Br J Urol 1997; 80:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/6\">",
"      Raman SR, Kate V, Ananthakrishnan N. Coital paraphimosis causing penile necrosis. Emerg Med J 2008; 25:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/7\">",
"      Cahill D, Rane A. Reduction of paraphimosis with granulated sugar. BJU Int 1999; 83:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/8\">",
"      Choe JM. Paraphimosis: current treatment options. Am Fam Physician 2000; 62:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/9\">",
"      Olson C. Emergency treatment of paraphimosis. Can Fam Physician 1998; 44:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/10\">",
"      Turner CD, Kim HL, Cromie WJ. Dorsal band traction for reduction of paraphimosis. Urology 1999; 54:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/11\">",
"      Little B, White M. Treatment options for paraphimosis. Int J Clin Pract 2005; 59:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/12\">",
"      Kamat N. Reduction of paraphimosis the simple way--the Dundee technique. BJU Int 1999; 84:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/13\">",
"      Houghton GR. The \"iced-glove\" method of treatment of paraphimosis. Br J Surg 1973; 60:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/14\">",
"      Coburn WM 3rd, Russell MA, Hofstetter WL. Sucrose as an aid to manual reduction of incarcerated rectal prolapse. Ann Emerg Med 1997; 30:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/15\">",
"      Kerwat R, Shandall A, Stephenson B. Reduction of paraphimosis with granulated sugar. Br J Urol 1998; 82:755.",
"     </a>",
"    </li>",
"    <li>",
"     Patricia Chambers. Paraphimosis reduction. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.904.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/17\">",
"      Barone JG, Fleisher MH. Treatment of paraphimosis using the \"puncture\" technique. Pediatr Emerg Care 1993; 9:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/18\">",
"      Hamdy FC, Hastie KJ. Treatment for paraphimosis: the 'puncture' technique. Br J Surg 1990; 77:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/19\">",
"      Waters TC, Sripathi V. Reduction of paraphimosis. Br J Urol 1990; 66:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/20\">",
"      Kumar V, Javle P. Modified puncture technique for reduction of paraphymosis. Ann R Coll Surg Engl 2001; 83:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/21\">",
"      Fuenfer MM, Najmaldin A. Emergency reduction of paraphimosis. Eur J Pediatr Surg 1994; 4:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/22\">",
"      Finkelstein JA. \"Puncture\" technique for treating paraphimosis. Pediatr Emerg Care 1994; 10:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/23\">",
"      DeVries CR, Miller AK, Packer MG. Reduction of paraphimosis with hyaluronidase. Urology 1996; 48:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/24\">",
"      Baigrie RJ. Treatment for paraphimosis. Br J Surg 1991; 78:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33543/abstract/25\">",
"      Raveenthiran V. Reduction of paraphimosis: a technique based on pathophysiology. Br J Surg 1996; 83:1247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6312 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.66.252.144-FC8D04C3D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33543=[""].join("\n");
var outline_f32_48_33543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patient counseling/Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Minimally invasive reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Invasive reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Topical medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Local anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Opioid analgesia and procedural sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - General anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adjuncts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Ice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Ace or Kerlix bandage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Osmotic agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Minimally invasive reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Manual compression and reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Traction with forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Invasive reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Puncture technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Glans penis aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Dorsal slit procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6312\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6312|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/0/19462\" title=\"figure 1\">",
"      Penis anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/42/22191\" title=\"figure 2\">",
"      Paraphim forcep technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/12/31938\" title=\"figure 3\">",
"      Dorsal penile block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/56/6016\" title=\"figure 4\">",
"      Manual reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/32/3598\" title=\"figure 5\">",
"      Puncture technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/21/16734\" title=\"figure 6\">",
"      Penis aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/31/41458\" title=\"figure 7\">",
"      Dorsal slit procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6312|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/33/23057\" title=\"picture 1\">",
"      Paraphimosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6312|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/46/748\" title=\"table 1\">",
"      Paraphimosis reduction summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/45/10971\" title=\"table 2\">",
"      Paraphimosis reduction tips",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30100?source=related_link\">",
"      Management of zipper injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=related_link\">",
"      Paraphimosis: Definition, pathophysiology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_48_33544="Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification";
var content_f32_48_33544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Judd W Moul, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33544/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/48/33544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum prostate specific antigen (PSA) is a sensitive and specific marker for prostate tissue. Serum PSA is elevated in 95 percent of men with advanced prostate cancer. Due to the sensitivity of serum PSA as a marker for prostate cancer, serial measurements are routinely obtained to detect early disease recurrence in men who have been treated for localized disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=see_link\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring PSA after treatment of localized prostate cancer typically leads to the identification of men with a PSA-only (biochemical) recurrence prior to the development of symptoms or signs of locally recurrent or metastatic disease, and no evidence of recurrent disease may be identifiable even with detailed evaluation. Many of these men are relatively young and otherwise healthy. Thus, intense interest has been focused upon their treatment, with attention on both survival and the impact of therapy on quality of life.",
"   </p>",
"   <p>",
"    The definition of PSA-only recurrence after treatment of clinically localized prostate cancer, its natural history, and risk stratification of these patients will be reviewed here. The diagnostic evaluation and management approaches for such patients are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=see_link\">",
"       \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIOCHEMICAL PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of PSA-only recurrence depends upon the initial treatment modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Radical prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All prostate tissue is removed during a successful radical prostatectomy. Postoperatively, detectable serum PSA using standard immunoassays is indicative of residual prostatic tissue, which presumably represents locoregional or systemic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether such disease is locally confined to the pelvis or represents systemic metastases is an important distinction with significant implications for patient management. If the serum PSA never falls to undetectable levels or is rising rapidly, systemic disease is more likely than residual disease in the prostatic bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], although some men will survive long-term after salvage RT without biochemical recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, if the PSA gradually rises after remaining undetectable for two or more years, an isolated local recurrence in the prostatic bed is more likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"     \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although various definitions of biochemical recurrence have been proposed, the most widely accepted criterion for patients who have undergone radical prostatectomy is that of the American Urological Association (AUA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/6\">",
"     6",
"    </a>",
"    ]. According to AUA guidelines, a biochemical recurrence is defined as a serum PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    which is confirmed by a second determination with a PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of biochemical failure is more complicated after radiation therapy (RT) than following radical prostatectomy. Some normal prostatic glandular tissue remains and serum PSA levels are unlikely to fall to undetectable levels following a course of RT. The interpretation of serum PSA levels is also complicated by the use of androgen deprivation therapy (ADT) in some patients with intermediate or high risk disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81452718\">",
"    <span class=\"h3\">",
"     Effect of RT on PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decline in serum PSA following RT is gradual and the mean time for the PSA to reach its nadir is 18 months or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/7\">",
"     7",
"    </a>",
"    ]. The rate of decline in the serum PSA does not appear to correlate with the risk of subsequent disease relapse.",
"   </p>",
"   <p>",
"    The nadir of the serum PSA concentration (ie, the lowest level to which it drops) is a strong indicator of treatment success following RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Although lower nadir values are associated with improved outcomes, no absolute level can distinguish treatment success from treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/7\">",
"     7",
"    </a>",
"    ]. A consensus panel convened by the American Society for Radiation Oncology (ASTRO) in 1996 recommended that the nadir PSA value be considered a prognostic factor similar to pretreatment variables such as serum PSA, Gleason score, and clinical tumor (T) stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'ASTRO criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Men who normalize their serum PSA after receiving a full course of RT seem to have more durable responses than those who do not; biochemical control rates beyond five years of follow-up are similar to those achieved after prostatectomy. This was illustrated in a report of 302 men followed for more than five years after receiving prostate RT (mean prostate dose 75 Gy); only 5 percent relapsed in years 5 to 8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/14\">",
"     14",
"    </a>",
"    ], a rate similar to that reported following radical prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relative stability of the PSA nadir is important, since a rising serum PSA probably indicates recurrence. Models have been developed to predict the future risk of a clinical relapse after RT in individual patients, based upon pretreatment variables, the RT dose, and the results of posttreatment serum PSA levels, but they are not yet available for clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     ASTRO criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variability in the definition of biochemical failure after RT can significantly influence the interpretation of treatment outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To standardize serum PSA testing for outcome assessment following RT, a 1996 American Society for Radiation Oncology (ASTRO) consensus panel defined biochemical recurrence following definitive RT as occurring after three consecutive PSA rises following a nadir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/13\">",
"     13",
"    </a>",
"    ]. The date of biochemical failure was halfway between the nadir and the date of first rise or any rise great enough to provoke the initiation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Phoenix criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second consensus conference was held by ASTRO in 2005 to address issues that had been identified in the 1996 definition of PSA failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PSA failure was defined in the revised \"Phoenix\" criteria as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A PSA rise by 2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or more above the nadir PSA is considered the standard definition for biochemical failure after external beam RT, regardless of whether or not a patient receives androgen deprivation therapy.",
"     </li>",
"     <li>",
"      The date of failure is defined by the time the rise in PSA is noted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     PSA bounce",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum PSA levels typically fall after RT and can then rise (\"bounce\") transiently, at a median of 12 to 18 months after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/18\">",
"     18",
"    </a>",
"    ]. This PSA bounce can occur in the absence of recurrent disease and does not necessarily signify a treatment failure or constitute an indication for therapeutic intervention.",
"   </p>",
"   <p>",
"    The PSA bounce phenomenon has been observed after low-dose rate brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/19\">",
"     19",
"    </a>",
"    ], high-dose rate brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/20\">",
"     20",
"    </a>",
"    ], and external beam RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The frequency with which such PSA bounces are observed varies, depending upon the definition used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/19,21\">",
"     19,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive data on the PSA bounce phenomenon come from a consecutive series of 820 patients treated with low-dose rate brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/23\">",
"     23",
"    </a>",
"    ]. The incidence of PSA bounce decreased with an increasing threshold to define a PSA bounce (30, 20, 13, and 10 percent, respectively, using definitions of 0.2, 0.4, 0.6, and 0.8",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    Regardless of the definition used, PSA bounces occurred significantly earlier with a PSA bounce compared to a biochemical failure, as defined by a PSA rise &gt;2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    above nadir (15 to 17 versus 34 months).",
"   </p>",
"   <p>",
"    The clinical implications of a PSA bounce are uncertain. Although some studies have shown an improved prognosis in patients who experience a PSA bounce [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/23-26\">",
"     23-26",
"    </a>",
"    ], other studies have reported in a worse prognosis in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no definitive methods to distinguish a PSA bounce from recurrent cancer. If an increase in the serum PSA is observed, the patient should be given reassurance, and the PSA can be repeated in three to six months. If the serum PSA continues to increase, a repeat biopsy can be considered, although the interpretation of a prostate biopsy performed following RT is difficult. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=see_link&amp;anchor=H29#H29\">",
"     \"Interpretation of prostate biopsy\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81452108\">",
"    <span class=\"h1\">",
"     PREDICTING BIOCHEMICAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors have been evaluated in an attempt to identify men at high risk of disease recurrence following radical prostatectomy or RT. In multivariate models, the most important determinants of outcome are the pretreatment serum PSA and Gleason score, as well as the anatomic extent of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=see_link\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most PSA recurrences are diagnosed early, but the time to PSA recurrence can be variable. In a series of 4561 men who had undergone radical prostatectomy, 31 percent eventually developed a PSA recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/29\">",
"     29",
"    </a>",
"    ]. Of these, approximately 90 percent occurred within the first five years. Patients with a pretreatment PSA &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and those with a Gleason score &lt;7 were more likely to have a delayed recurrence.",
"   </p>",
"   <p>",
"    Several models or nomograms to predict outcome are available that are based upon pretreatment factors, while others incorporate the pathologic examination of the surgical specimen and, in one case, the duration of time that a man has remained free of progression since surgery. These approaches are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9704?source=see_link&amp;anchor=H15#H15\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Nomograms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81453304\">",
"    <span class=\"h1\">",
"     PROGNOSIS AFTER BIOCHEMICAL FAILURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of prostate cancer following a PSA relapse does not necessarily predict the development of metastases or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. This is illustrated by a series of 1973 men treated with radical prostatectomy at Johns Hopkins between 1981 and 2010 who developed a biochemical recurrence (PSA &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    following radical prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/32\">",
"     32",
"    </a>",
"    ]. Of these, 642 were observed without further treatment; and within this group, 450 had sufficient data for the calculation of PSA doubling time.",
"   </p>",
"   <p>",
"    With a median follow-up of eight years, 134 patients (30 percent) had developed metastases, and the median metastasis-free survival was 10.0 years. Multivariate analysis found that independent factors associated with the development of metastases were the PSA doubling time (&lt;3.0 versus 3.0-8.9 versus 9.0-14.9 versus &ge;15.0 months) and the Gleason score from the radical prostatectomy specimen (&le;6 versus 7 versus 8-10).",
"   </p>",
"   <p>",
"    Data from an earlier analysis of 321 men at this institution were used to construct tables (the \"Pound tables\") to predict the likelihood of being free of metastases following a biochemical failure after radical prostatectomy (",
"    <a class=\"graphic graphic_table graphicRef76126 \" href=\"mobipreview.htm?4/22/4460\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/33\">",
"     33",
"    </a>",
"    ]. A similar table to estimate the 10- and 15-year risk of prostate cancer-related death in men with a rising PSA after radical prostatectomy based upon 379 such men was published in 2005 (",
"    <a class=\"graphic graphic_table graphicRef54638 \" href=\"mobipreview.htm?32/62/33772\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar models have been developed to predict the future risk of clinical relapse and death in individual patients initially treated with radiation therapy, based upon pretreatment variables, radiation dose, and the results of serial posttreatment serum PSA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/15,34\">",
"     15,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81453347\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several parameters (eg, PSA-doubling time, Gleason score, PSA response to salvage ADT) have been studied to distinguish men who are likely to develop \"clinically significant\" disease following either radical prostatectomy or RT from those who have more indolent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. This information can be an important factor in determining whether and when to initiate further treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81453790\">",
"    <span class=\"h3\">",
"     Predictors of distant failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same features that predict biochemical failure after initial treatment for prostate cancer provide insight into the likely natural history of the disease following biochemical recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/35\">",
"     35",
"    </a>",
"    ]. These include the clinical features at original presentation (tumor [T] stage, PSA level, PSA velocity, biopsy Gleason score) as well as pathologic findings at the time of prostatectomy for men who have undergone surgery (T stage, nodal and margin status, and Gleason score). As such, these features can aid in treatment decisions in men with a rising PSA after local treatment. (See",
"    <a class=\"local\" href=\"#H81452108\">",
"     'Predicting biochemical failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who have short intervals to PSA failure and rapid PSA-DT after prostatectomy or radiation therapy have significantly increased rates of distant metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/30,35-37\">",
"       30,35-37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In several studies, the presence of pathologic nodal or seminal vesicle involvement, or Gleason score &ge;8 disease at the time of initial prostatectomy predict for occult distant metastatic disease, and are associated with poor salvage rates with local-only salvage therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/5,38-43\">",
"       5,38-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combining posttreatment PSA kinetics and the pathologic findings from prostatectomy can further optimize appropriate patient selection for salvage local therapy by eliminating those men who are at exceptionally high risk of systemic recurrence. In one study, investigators constructed a flow diagram to predict four-year actuarial progression-free probabilities after salvage RT (",
"      <a class=\"graphic graphic_figure graphicRef51979 \" href=\"mobipreview.htm?32/62/33773\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/41\">",
"       41",
"      </a>",
"      ]. Men with Gleason score &ge;8 and a preradiation PSA &ge;2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      had the worst four-year progression-free survival probability (12 percent), while those with Gleason scores of &le;7, preradiation PSA &lt;2",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      positive surgical margins, and a PSA-DT &gt;10 months had the highest (77 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     PSA doubling time and Gleason score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies indicate that a long PSA doubling time (PSA-DT) predicts both clinical metastasis-free survival and prostate cancer-specific mortality in men with a rising serum PSA after radical prostatectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/36,44-49\">",
"     36,44-49",
"    </a>",
"    ]. The PSA-DT is less well studied after external beam RT and has not been validated after brachytherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/25,50\">",
"     25,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of PSA-DT is illustrated by the largest series, which studied the outcomes in 8669 men with clinically localized or locally advanced nonmetastatic prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/46\">",
"     46",
"    </a>",
"    ]. Of these men, 5918 initially were treated surgically and 2751 were managed with RT. Men with a PSA-DT of &lt;3 months had a 20-fold increased risk of dying of prostate cancer compared to those with a PSA-DT of &ge;3 months (",
"    <a class=\"graphic graphic_table graphicRef55120 \" href=\"mobipreview.htm?41/4/42059\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A later analysis found that the use of the Gleason score in conjunction with PSA-DT provided a better estimate of prostate cancer-specific mortality in men with a rising PSA following RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with a PSA-DT &lt;3 months, prostate cancer-specific mortality rates five years after biochemical failure were 35 and 75 percent with Gleason scores of &le;7 and &ge;8, respectively.",
"     </li>",
"     <li>",
"      For men with PSA-DT &ge;3 months, the five-year prostate cancer-specific mortality rates for Gleason score &le;7 and &ge;8 disease were 4 and 15 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the view that men who have a short PSA-DT and a Gleason score &ge;8 disease are at particularly high risk of dying from prostate cancer and are unlikely to achieve long-term disease control from local-only salvage therapies. (See",
"    <a class=\"local\" href=\"#H81453790\">",
"     'Predictors of distant failure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, the number of men with a PSA-DT &lt;3 months was relatively small. Among those who have a biochemical recurrence with a somewhat longer PSA-DT, prostate cancer is still a major cause of mortality. In one study of men with a rising PSA following prostatectomy and a PSA-DT &lt;15 months, prostate cancer accounted for approximately 90 percent of all deaths by 15 years after biochemical recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link&amp;anchor=H4#H4\">",
"     \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\", section on 'Timing of ADT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caution should be exercised when an ultrasensitive PSA assay is used to calculate the PSA-DT. The studies that demonstrated the importance of PSA-DT were based upon calculations when level of detectability of the serum PSA was &ge;0.2",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Ultrasenstive PSA assays have a lower limit of detection of 0.01",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or less, and doubling times using such an assay for the first detection of PSA following treatment correlate poorly with the older methodology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     PSA \"response\" to ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"PSA response\" to androgen deprivation therapy (ADT) following biochemical recurrence may be useful as an intermediate end point for prognosis and to predict the time to prostate cancer death in men with biochemical recurrence following radical prostatectomy or RT.",
"   </p>",
"   <p>",
"    Men with a rapid rise in PSA prior to salvage hormonal therapy or a slow decline after treatment are likely to have tumor that is not responsive to salvage hormonal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/52\">",
"     52",
"    </a>",
"    ]. In contrast, those with a more rapid rate of post-therapy PSA decline or a more protracted rise in pre-salvage therapy PSA had more favorable outcomes. Neither the post-therapy rate of PSA decline by itself, nor the PSA doubling time, nor the timing of salvage hormone therapy predicted for the time to prostate cancer-specific death following salvage hormone therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8461069\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variable natural history for men with a PSA-only recurrence following definitive therapy for localized prostate cancer needs to be integrated into the decision of when and how to proceed with treatment. In addition to prognostic factors such as the recurrence-free interval and the PSA doubling time, other factors that should be considered include the patient&rsquo;s age and life expectancy, associated comorbidities, and psychological factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33544/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic evaluation and approach to treatment are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=see_link\">",
"       \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate specific antigen (PSA) is a sensitive and specific marker for prostate cancer. Monitoring PSA after treatment of localized prostate cancer leads to the identification of men with a PSA-only (biochemical) recurrence, when there are no symptoms or signs of locally recurrent or metastatic disease.",
"     </li>",
"     <li>",
"      The definition of a PSA-only recurrence is based upon the initial treatment received by the patient:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have undergone a radical prostatectomy, the American Urologic Association (AUA) defines a biochemical recurrence as a serum PSA &ge;0.2",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      which is confirmed by a second determination with a PSA &ge;0.2",
"      <span class=\"nowrap\">",
"       ng/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radical prostatectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients initially treated with external beam radiation therapy, the American Society for Therapeutic Radiology and Oncology has developed the Phoenix criteria, which define a PSA recurrence as a PSA rise by 2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or more above the nadir PSA, regardless of whether or not a patient receives androgen deprivation therapy. The date of failure is defined by the time the rise in PSA is noted. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Phoenix criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The natural history of disease for men with a PSA-only (biochemical) recurrence is often very prolonged. A biochemical recurrence does not necessarily predict the subsequent development of metastatic disease and is not necessarily an indication for systemic treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various clinical and pathologic factors can be used to predict an increased likelihood of clinical disease recurrence and death from prostate cancer. The most important of these are a short PSA doubling time and higher Gleason score. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'PSA doubling time and Gleason score'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/1\">",
"      Ravery V. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/2\">",
"      Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/3\">",
"      Partin AW, Pearson JD, Landis PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/4\">",
"      Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/5\">",
"      Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/6\">",
"      Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/7\">",
"      Crook JM, Choan E, Perry GA, et al. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. Urology 1998; 51:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/8\">",
"      Critz FA, Levinson AK, Williams WH, et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997; 49:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/9\">",
"      Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/10\">",
"      Perez CA, Michalski JM, Lockett MA. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys 2001; 49:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/11\">",
"      Yock TI, Zietman AL, Shipley WU, et al. Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 54:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/12\">",
"      Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006; 64:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/13\">",
"      Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/14\">",
"      Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/15\">",
"      Taylor JM, Yu M, Sandler HM. Individualized predictions of disease progression following radiation therapy for prostate cancer. J Clin Oncol 2005; 23:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/16\">",
"      Kupelian PA, Mahadevan A, Reddy CA, et al. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 2006; 68:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/17\">",
"      Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/18\">",
"      Satoh T, Ishiyama H, Matsumoto K, et al. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int 2009; 103:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/19\">",
"      Caloglu M, Ciezki J. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology 2009; 74:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/20\">",
"      Bachand F, Martin AG, Beaulieu L, et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009; 73:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/21\">",
"      Pickles T, British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2006; 64:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/22\">",
"      Horwitz EM, Levy LB, Thames HD, et al. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 2006; 107:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/23\">",
"      Caloglu M, Ciezki JP, Reddy CA, et al. PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol Biol Phys 2011; 80:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/24\">",
"      Hinnen KA, Monninkhof EM, Battermann JJ, et al. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol Biol Phys 2012; 82:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/25\">",
"      Ciezki JP, Reddy CA, Garcia J, et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006; 64:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/26\">",
"      Patel C, Elshaikh MA, Angermeier K, et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology 2004; 63:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/27\">",
"      Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 2003; 56:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/28\">",
"      Merrick GS, Butler WM, Wallner KE, et al. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/29\">",
"      Caire AA, Sun L, Ode O, et al. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology 2009; 74:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/30\">",
"      Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/31\">",
"      Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 2002; 52:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/32\">",
"      Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/33\">",
"      Eisenberger ME, Partin AW, Pound C, et al. Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy (abstract #1527). Proc Am Soc Clin Oncol 2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/34\">",
"      D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/35\">",
"      Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005; 23:8192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/36\">",
"      Zhou P, Chen MH, McLeod D, et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23:6992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/37\">",
"      Buyyounouski MK, Pickles T, Kestin LL, et al. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012; 30:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/38\">",
"      D'Amico AV, Wu Y, Chen MH, et al. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score &lt;/= 7. Cancer 2000; 89:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/39\">",
"      Leventis AK, Shariat SF, Kattan MW, et al. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/40\">",
"      Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000; 163:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/41\">",
"      Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/42\">",
"      D'Amico AV, Whittington R, Malkowicz SB, et al. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 2000; 18:3240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/43\">",
"      Katz MS, Zelefsky MJ, Venkatraman ES, et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003; 21:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/44\">",
"      Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007; 25:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/45\">",
"      Ward JF, Zincke H, Bergstralh EJ, et al. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004; 172:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/46\">",
"      D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/47\">",
"      Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005; 23:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/48\">",
"      Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004; 171:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/49\">",
"      Lee AK, Levy LB, Cheung R, Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 2005; 63:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/50\">",
"      Valicenti RK, DeSilvio M, Hanks GE, et al. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys 2006; 66:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/51\">",
"      Teeter AE, Presti JC Jr, Aronson WJ, et al. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int 2009; 104:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/52\">",
"      D'Amico AV, Moul JW, Carroll PR, et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004; 96:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33544/abstract/53\">",
"      Dale W, Hemmerich J, Bylow K, et al. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study. J Clin Oncol 2009; 27:1557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6950 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33544=[""].join("\n");
var outline_f32_48_33544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DEFINITION OF BIOCHEMICAL PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81452718\">",
"      - Effect of RT on PSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - ASTRO criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Phoenix criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - PSA bounce",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81452108\">",
"      PREDICTING BIOCHEMICAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81453304\">",
"      PROGNOSIS AFTER BIOCHEMICAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81453347\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H81453790\">",
"      - Predictors of distant failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PSA doubling time and Gleason score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PSA \"response\" to ADT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8461069\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6950|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/62/33773\" title=\"figure 1\">",
"      Prob PC death PSA doubling time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/22/4460\" title=\"table 1\">",
"      Pound tables 2003",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/62/33772\" title=\"table 2\">",
"      15year prost CA surv rising PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/4/42059\" title=\"table 3\">",
"      Prostate CA mortality by PSA DT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=related_link\">",
"      Initial staging and evaluation of men with newly diagnosed prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=related_link\">",
"      Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_48_33545="Allergic bronchopulmonary aspergillosis";
var content_f32_48_33545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergic bronchopulmonary aspergillosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Praveen Akuthota, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33545/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/48/33545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction, often in patients with asthma or cystic fibrosis (CF), that occurs when bronchi become colonized by Aspergillus species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology, diagnosis, and treatment of ABPA will be reviewed here. General issues related to bronchiectasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of ABPA remains incompletely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. There is no relation between the intensity of exposure to airborne Aspergillus spores and rates of sensitization to the fungus as measured by skin testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/7\">",
"     7",
"    </a>",
"    ]. Although all spores that are inhaled in sufficient quantities can behave as allergens, the normally low level of IgG against fungal antigens in the circulation and the low anti-fungal secretory IgA in bronchoalveolar fluid suggest that healthy individuals are able to effectively eliminate fungal spores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In contrast, exposure of atopic individuals to fungal spores or mycelial fragments results in the formation of IgE and IgG antibodies.",
"   </p>",
"   <p>",
"    T cells also play an important role in ABPA. There are increases in Th2 CD4+ cell responses to Aspergillus antigens both in the bronchoalveolar lymphoid tissue and systemically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5\">",
"     5",
"    </a>",
"    ]. Aspergillus-responsive T cells generate cytokines interleukin (IL)-4, IL-5, and IL-13, which in turn account for the increases in eosinophilia and IgE in ABPA. In one study, T cell clones specific to the Asp f 1 antigen of A. fumigatus were established from the peripheral blood of three patients with ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/10\">",
"     10",
"    </a>",
"    ]. The majority of these clones were CD4+ cells of the Th2 phenotype, which produce interleukin (IL)-4 and IL-5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/10\">",
"     10",
"    </a>",
"    ]. The response to the Asp f 1 antigen was HLA restricted, being mediated exclusively by either HLA-DR2 or HLA-DR5 and was restricted to specific T cell receptor V-beta chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, there is increased sensitivity of B cells, T cells, NK cells, and eosinophils to IL-4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, the costimulatory molecule OX40 ligand was crucial for driving Th2 responses to A. fumigatus in the CD4+ cells of patients with CF and ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/11\">",
"     11",
"    </a>",
"    ]. Heightened Th2 reactivity in these patients correlated with lower mean serum vitamin D levels.",
"   </p>",
"   <p>",
"    Aspergillus colonization of the asthmatic airway leads to vigorous IgE- and IgG-mediated immune responses superimposed on the asthmatic milieu. In spite of these vigorous responses in ABPA, the fungus is able to colonize the airway and cause recurrent symptoms. Proteolytic enzymes and mycotoxins released by fungi, in concert with Th2-mediated eosinophilic inflammation and IL-8 mediated neutrophilic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/12\">",
"     12",
"    </a>",
"    ], may result in airway damage and central bronchiectasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABPA is characterized pathologically by mucoid impaction of the bronchi, eosinophilic pneumonia, and bronchocentric granulomatosis in addition to the histologic features of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Septated hyphae with acute dichotomous branching may be seen in the mucus-filled bronchial lumen, but fungi do not invade the mucosa. Aspergillus is cultured from the sputum in up to two-thirds of patients with ABPA, but hyphae may not be seen by direct microscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44484?source=see_link\">",
"     \"Bronchocentric granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABPA occurs primarily in patients with asthma (2 to 32 percent of asthma patients) or with CF (1 to 15 percent of CF patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. The clinical picture of ABPA is dominated by asthma complicated by recurrent episodes of bronchial obstruction, fever, malaise, expectoration of brownish mucus plugs, peripheral blood eosinophilia, and at times hemoptysis. Wheezing is not always evident, and some patients present with asymptomatic pulmonary consolidation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with asthma, a staging system for ABPA has been developed to categorize the differing presentations of ABPA (",
"    <a class=\"graphic graphic_table graphicRef76368 \" href=\"mobipreview.htm?28/1/28699\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/14\">",
"     14",
"    </a>",
"    ]. These stages are not necessarily progressive phases of the disease; patients need not inevitably pass from one stage to another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest radiograph may show parenchymal infiltrates (usually involving the upper lobes), atelectasis due to mucoid impaction, and a number of findings characteristic of bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/15\">",
"     15",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Tram line\" shadows due to thickened walls of nondilated bronchi.",
"     </li>",
"     <li>",
"      \"Parallel lines\" due to the presence of ectatic bronchi.",
"     </li>",
"     <li>",
"      Ring shadows due to mucus-filled bronchi or small abscesses seen en face next to pulmonary blood vessels.",
"     </li>",
"     <li>",
"      \"Toothpaste shadows\" due to mucoid impacted second- to fourth-order bronchi.",
"     </li>",
"     <li>",
"      \"Gloved finger shadows\" due to intrabronchial exudates with bronchial wall thickening; these appear as branched tubular radiodensities 2 to 3 cm long and 5 to 8 mm wide that extend from the hilus.",
"     </li>",
"     <li>",
"      Perihilar infiltrates may simulate hilar adenopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     High resolution computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution computed tomography (HRCT) scan of the thorax may show widespread proximal cylindrical bronchiectasis with upper lobe predominance and bronchial wall thickening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64077 \" href=\"mobipreview.htm?3/38/3682\">",
"     image 1",
"    </a>",
"    ). However, central bronchiectasis with normal tapering of distal bronchi has not been a consistently sensitive or specific marker for ABPA in all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. In one series of 15 patients, for example, the sensitivity of central bronchiectasis on chest CT as a diagnostic feature for ABPA was only 37 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to bronchiectasis, other findings on HRCT include mucus plugging, high attenuation mucus, atelectasis, peripheral airspace consolidation, or ground-glass attenuation, and possibly mosaic perfusion or air trapping [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. Using these criteria, in comparison with other forms of eosinophilic lung diseases, radiologists made a correct diagnosis of ABPA in 84 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/17\">",
"     17",
"    </a>",
"    ]. Coordination between clinical and CT findings are advised to optimize the diagnosis of ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients have airflow obstruction and air trapping with reduced FEV1 and increased residual volume; a positive bronchodilator response is found in less than one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/22\">",
"     22",
"    </a>",
"    ]. Individuals with bronchiectasis or fibrosis may exhibit a mixed obstructive and restrictive pattern. A minority of patients has a reduction in diffusing capacity, an abnormality that may be more common in the presence of bronchiectasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no individual test to establish the diagnosis of ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/1,5,6,23\">",
"     1,5,6,23",
"    </a>",
"    ]. The major reason for pursuing the diagnosis is that the condition responds to glucocorticoid therapy, and early detection and treatment may reduce the risk of progression to fibrotic disease. The diagnosis is usually confirmed by use of clinical, radiographic, and immunologic criteria.",
"   </p>",
"   <p>",
"    The major diagnostic features of classic ABPA include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of asthma",
"     </li>",
"     <li>",
"      Immediate skin test reactivity to Aspergillus antigens",
"     </li>",
"     <li>",
"      Precipitating serum antibodies to A. fumigatus",
"     </li>",
"     <li>",
"      Serum total IgE concentration &gt;417",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (&gt;1000",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Peripheral blood eosinophilia",
"      <span class=\"nowrap\">",
"       &gt;500/mm(3)",
"      </span>",
"     </li>",
"     <li>",
"      Lung infiltrates on chest x-ray or chest HRCT",
"     </li>",
"     <li>",
"      Central bronchiectasis on chest CT",
"     </li>",
"     <li>",
"      Elevated specific serum IgE and IgG to A. fumigatus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the first four criteria above are met but there is no accompanying central bronchiectasis, then a diagnosis of ABPA-S (seropositive) is given.",
"   </p>",
"   <p>",
"    The minimal essential criteria to diagnose ABPA-CB (central bronchiectasis) are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of asthma",
"     </li>",
"     <li>",
"      Immediate skin test reactivity to A. fumigatus",
"     </li>",
"     <li>",
"      Elevated serum total IgE",
"     </li>",
"     <li>",
"      Central bronchiectasis",
"     </li>",
"     <li>",
"      Elevated specific serum IgE and IgG to A. fumigatus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A skin prick test should be the first step in an asthmatic being evaluated for ABPA. A negative prick skin test followed by negative intradermal reactivity to Aspergillus virtually excludes ABPA from consideration.",
"   </p>",
"   <p>",
"    If the prick test is positive, serum total IgE and precipitins to Aspergillus should be assayed. ABPA is excluded if the serum total IgE concentration is less than 1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or if serum precipitins to Aspergillus are negative. IgE levels, like levels of blood eosinophilia, may decrease but generally do not normalize if the patient is receiving glucocorticoids.",
"   </p>",
"   <p>",
"    If the serum total IgE is &gt;417",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    (&gt;1000",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and the precipitin test is positive for Aspergillus, then a presumptive diagnosis of ABPA is made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/24\">",
"     24",
"    </a>",
"    ]. Though we report 417",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    (1000",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    as the minimum serum IgE concentration considered to be elevated for a diagnosis of ABPA, several investigators have used a minimum concentration of 1000",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    (2400",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/4\">",
"     4",
"    </a>",
"    ]. Determination of specific anti-Aspergillus fumigatus IgE and IgG should be performed in patients with an elevated serum IgE concentration and a positive precipitin test: the presence of at least a two-fold elevation in specific anti-Aspergillus IgE and IgG indices (compared with pooled serum of Aspergillus-sensitized non-ABPA asthmatics) indicates seropositive ABPA rather than sensitization to Aspergillus in asthmatics without ABPA.",
"   </p>",
"   <p>",
"    A chest x-ray should be obtained during the initial visit to detect parenchymal infiltrates or bronchiectasis. A negative chest x-ray should be followed by an HRCT scan of the thorax only if a prick skin test and serologic studies are positive. Bronchiectasis by HRCT is present in 15 to 18 percent of non-ABPA asthmatics with positive immediate skin reactivity to Aspergillus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/18,19,25\">",
"     18,19,25",
"    </a>",
"    ]. One report compared 17 patients with ABPA with 11 with asthma and a positive skin test to A. fumigatus but not other features of ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/25\">",
"     25",
"    </a>",
"    ]. Bronchiectasis by CT scan was much more common in the patients with ABPA (42 versus 5 percent of lobes).",
"   </p>",
"   <p>",
"    Although cases have been reported, the diagnosis of ABPA without concurrent asthma must be made with care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. One series described 11 such patients with ABPA who did not have asthma by history and who had negative bronchodilator responsiveness. Some of these individuals subsequently developed asthma, suggesting that they were diagnosed during a preclinical phase of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/26\">",
"     26",
"    </a>",
"    ]. Three of the 11 patients had hypersensitivity to fungi other than Aspergillus, and differences in the host responses to these pathogens may have accounted for the absence of clinical asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     ABPA versus conventional asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABPA is frequently raised as a diagnostic possibility in patients with asthma, particularly if immediate skin test reactivity to Aspergillus is present. Estimates of the frequency of ABPA among asthmatics vary considerably. As examples, a university tertiary care allergy clinic with special interest in ABPA ultimately diagnosed ABPA in 6 percent of asthmatics with immediate reactivity to Aspergillus, but ABPA has been documented in up to 32 percent of patients with asthma and skin test reactivity to Aspergillus in other series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/13,28-31\">",
"     13,28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many asthmatics have one or more findings of ABPA, but do not meet full criteria for the diagnosis. The presence of isolated ABPA features may cause diagnostic confusion, but does not appear to affect prognosis. Features of ABPA which are found commonly in asthmatics without ABPA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive immediate skin reactivity to A. fumigatus, which is present in 20 to 30 percent of all asthmatics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/29,32\">",
"       29,32",
"      </a>",
"      ]. The label \"severe asthma with fungal sensitization\" has been increasingly used to describe such patients, as well as those with skin test reactivity to other fungal antigens. As in ABPA,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      therapy has been demonstrated to be of potential benefit in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25689?source=see_link\">",
"       \"The role of fungi (molds) in human disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Positive serum precipitins to Aspergillus, which occur in 10 percent of asthmatics without ABPA, and in 10 percent of nonasthmatic patients with chronic lung disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent mucoid impaction and atelectasis, particularly among poorly controlled asthmatics.",
"     </li>",
"     <li>",
"      Peripheral blood eosinophilia and elevation of serum total IgE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ABPA in cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to establish the diagnosis of ABPA in patients with CF, but identification and treatment of the disease may result in improvement in symptoms and pulmonary function. The prevalence of ABPA in children with CF appears to be 2 to 15 percent, while adults with CF may have a lower prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5,36-42\">",
"     5,36-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cystic Fibrosis Foundation Consensus Conference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5\">",
"     5",
"    </a>",
"    ] has identified diagnostic criteria for ABPA in CF:",
"   </p>",
"   <p>",
"    Classic case:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, decline in pulmonary function, increased sputum) not attributable to another etiology.",
"     </li>",
"     <li>",
"      Serum total IgE of &gt;1000",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (&gt;2400",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      unless patient is receiving systemic glucocorticoids; if so, retest when patient is off steroids.",
"     </li>",
"     <li>",
"      Immediate skin test reactivity to Aspergillus or in vitro presence of anti-Aspergillus IgE antibodies.",
"     </li>",
"     <li>",
"      Precipitating antibodies to A. fumigatus or serum IgG antibody to A. fumigatus.",
"     </li>",
"     <li>",
"      New or recent abnormalities on chest x-ray (infiltrates or mucus plugging) or chest CT (bronchiectasis) that do not clear with antibiotics and physiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The minimal diagnostic criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exercise-induced asthma, decline in pulmonary function, increased sputum) not attributable to another etiology.",
"     </li>",
"     <li>",
"      Total serum IgE &gt;500",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (&gt;1200",
"      <span class=\"nowrap\">",
"       ng/mL);",
"      </span>",
"      if total IgE is 200 to 500",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      [480 to 1200",
"      <span class=\"nowrap\">",
"       ng/mL],",
"      </span>",
"      repeat testing in one to three months; if the patient is taking steroids, repeat when steroid treatment is discontinued.",
"     </li>",
"     <li>",
"      Immediate skin test reactivity to Aspergillus or in vitro presence of anti-Aspergillus IgE antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plus one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum precipitins or IgG antibody to A. fumigatus.",
"     </li>",
"     <li>",
"      New or recent abnormalities on chest x-ray (infiltrates or mucus plugging) or chest CT (bronchiectasis) that does not clear with antibiotics and physiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CF is complicated by recurrent pulmonary infections, bronchiectasis, and microbial colonization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .) ABPA should be suspected if patients with pulmonary infiltrates or clinical deterioration do not respond to one week of antibiotic treatment. Consensus Conference guidelines for screening for ABPA in CF include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain a high level of suspicion for ABPA in CF patients &gt;6 years of age.",
"     </li>",
"     <li>",
"      Determine the total serum IgE concentration annually. If the concentration is &gt;500",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (&gt;1200",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      evaluate for anti-Aspergillus IgE by determining skin test reactivity or in vitro testing for IgE to A. fumigatus.",
"     </li>",
"     <li>",
"      If the serum IgE is 200 to 500",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (480 to 1200",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      repeat the measurement if there is increased clinical suspicion of ABPA and perform further diagnostic tests (eg, evaluate skin tests, in vitro tests for anti-Aspergillus fumigatus IgE, IgG and precipitins, chest x-ray).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with glucocorticoids should be instituted, and therapy should result in a reduction in IgE level. In one retrospective series of 16 patients with CF and ABPA, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    was associated with a 47 percent reduction in average daily glucocorticoid dose and a 55 percent reduction in the number of acute ABPA episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/41\">",
"     41",
"    </a>",
"    ]. ABPA and other semi-invasive manifestations of Aspergillus infection (eg, bronchial aspergillosis, wound or anastomotic infection) can occur after lung transplantation in CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ABPA and pulmonary eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of transitory lung infiltrates associated with peripheral blood eosinophilia should always include ABPA, which is the most common cause of this syndrome in Great Britain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    .) Such findings should also prompt consideration of other diagnoses, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute or chronic eosinophilic pneumonia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1255?source=see_link\">",
"       \"Idiopathic acute eosinophilic pneumonia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug-induced eosinophilic pneumonia",
"     </li>",
"     <li>",
"      Churg-Strauss syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypereosinophilic syndromes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tropical eosinophilic pneumonia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2532?source=see_link\">",
"       \"Tropical filarial pulmonary eosinophilia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Loeffler's pneumonia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/25/11668?source=see_link\">",
"       \"Pulmonary manifestations of ascariasis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Autoimmune diseases such as rheumatoid arthritis, pernicious anemia, and sarcoidosis",
"     </li>",
"     <li>",
"      Complications of crack-cocaine abuse (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=see_link\">",
"       \"Pulmonary complications of cocaine abuse\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prick test and assay of serum Aspergillus precipitins should be performed if the diagnosis of ABPA is entertained. A negative prick skin test and the absence of precipitins to Aspergillus virtually exclude ABPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ABPA and bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bronchiectasis should be evaluated for ABPA unless the patient has a history suggestive of a prior necrotizing pneumonia. Although central bronchiectasis is often seen in ABPA, it is a nonspecific finding. As an example, one series of 168 patients found that CT characteristics of bronchiectasis failed to differentiate disease caused by ABPA from that due to hypogammaglobulinemia, ciliary dysfunction, CF, or idiopathic causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/16\">",
"     16",
"    </a>",
"    ]. The bronchiectasis was more likely to be widespread and central in ABPA than in other causes, but these findings were not predictive in the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ABPA aims to control episodes of acute inflammation and to limit progressive lung injury. Glucocorticoids are most commonly used, although there is evidence of benefit from combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The 2008 Infectious Diseases Society of America guidelines on the treatment of aspergillosis recommend that therapy of ABPA should consist of a combination of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is a reasonable alternative to itraconazole since it is well tolerated and well absorbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are effective for controlling ABPA but are associated with significant immunosuppressive and metabolic side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/28,45,49,50\">",
"     28,45,49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The glucocorticoid dose varies with the stage of disease. Inhaled steroids may help control symptoms of asthma but do not have documented efficacy in preventing acute episodes of ABPA. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Staging system'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the specific choice of glucocorticoid regimen often varies among clinicians and is tailored to the individual patient, we generally use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute flare of ABPA (stage I) is treated with 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for 14 days, followed by conversion to an every other day regimen and a slow taper over three to six months.",
"     </li>",
"     <li>",
"      The clinical response to glucocorticoids should be monitored with serial monthly or bimonthly measurement of the serum total IgE concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/51\">",
"       51",
"      </a>",
"      ]. Resolution of radiographic infiltrates and clinical improvement (remission or stage II disease) generally are accompanied by at least a 35 percent reduction in serum total IgE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/4\">",
"       4",
"      </a>",
"      ]. However, patients with a baseline IgE level &lt;2500",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (&lt;6000",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      may not have as large of a percentage decrease in IgE in response to glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/52\">",
"       52",
"      </a>",
"      ]. An increase in serum IgE may herald or accompany lung infiltrates and peripheral eosinophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/51,53\">",
"       51,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent exacerbations or flares (stage III) are frequent and are accompanied by at least a 100 percent rise in serum total IgE over baseline. We recommend a tapered glucocorticoid regimen as detailed above for stage I disease. 20 to 35 percent of flares are asymptomatic and are detected radiographically and serologically. Chest x-rays should be obtained if signs of an asymptomatic flare are detected during physical examination or if a patient has an established pattern of recurrent, asymptomatic flares.",
"     </li>",
"     <li>",
"      Stage IV disease (glucocorticoid-dependent asthma) is present when a patient cannot discontinue glucocorticoids without a recrudescence of asthma symptoms.",
"     </li>",
"     <li>",
"      Stage II disease (remission) and stage V disease (fibrotic lung disease) do not warrant glucocorticoid treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antifungal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials, a retrospective cohort study, and a small prospective study have demonstrated the utility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in addition to glucocorticoids for the therapy of ABPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/54-58\">",
"     54-58",
"    </a>",
"    ]. The larger of the randomized trials compared itraconazole with placebo in 55 patients already receiving glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/54\">",
"     54",
"    </a>",
"    ]. The addition of itraconazole for 16 weeks was associated with a significant increase in the likelihood of a clinical response (46 versus 19 percent). A response was defined as a reduction of at least 50 percent in the glucocorticoid dose, a decrease of at least 25 percent in the serum IgE concentration, and one of the following: an improvement of at least 25 percent in exercise tolerance or pulmonary function tests, or partial or complete resolution of pulmonary infiltrates. Adverse effects were similar in both groups. While total IgE decreases with therapy, specific IgE antibodies against A. fumigatus may not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is thought to work by reducing the antigenic stimulus for bronchial inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/48\">",
"     48",
"    </a>",
"    ]. The antifungal effects can be inferred by the ability of itraconazole to reduce specific Aspergillus IgG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/56\">",
"     56",
"    </a>",
"    ]. Another possible contributor to itraconazole action in ABPA is by impairing metabolism of the glucocorticoid, thereby raising plasma levels. This effect is best described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    but may not be important with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , which is the active form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The development of Cushing's syndrome has been recognized in ABPA patients treated with itraconazole and glucocorticoids, with most case reports involving inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Such patients are also at risk for adrenal insufficiency due to inhibition of cortisol synthesis, which becomes apparent with glucocorticoid dose reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/63-65\">",
"     63-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many clinicians no longer use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for invasive forms of pulmonary aspergillosis and use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    instead. Successful use of voriconazole in ABPA has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Whether voriconazole is superior to itraconazole in ABPA remains unknown, although voriconazole has distinct advantages to itraconazole, such as improved tolerance and bioavailability. There are no data on the efficacy of other newer azole agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , in ABPA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31529?source=see_link\">",
"     \"Treatment of chronic pulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in patients with ABPA has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417489496\">",
"    <span class=\"h3\">",
"     Approach to antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    for 16 weeks in all patients who require substantial doses of glucocorticoids, with the goal of enabling a reduction in the glucocorticoid dose. We also suggest itraconazole or voriconazole in patients with relapsed ABPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417489503\">",
"    <span class=\"h4\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    regimen in adults is 200 mg three times a day for three days followed by 200 mg twice daily with food. Children should receive 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day given either once a day, or if the total dose exceeds 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    given in divided twice daily doses with food. Liver function tests should be monitored monthly for any evidence of hepatotoxicity. It is recommended that itraconazole serum concentrations be obtained to ensure appropriate absorption of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of azoles\", section on 'Hepatotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H27#H27\">",
"     \"Pharmacology of azoles\", section on 'Itraconazole'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The liquid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , given in the same dosages noted above, overcomes problems caused by poor absorption of the capsule and achieves approximately 30 percent higher concentrations in the serum at the same dose. The solution should be given on an empty stomach to achieve the highest serum concentrations. However, more gastrointestinal upset occurs with the solution formulation, which precludes its use in some patients.",
"   </p>",
"   <p>",
"    Acid-blocking drugs should be avoided when the capsule formulation is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417489578\">",
"    <span class=\"h4\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    dosing for adults involves a loading dose of 400 mg orally every 12 hours for two doses, followed by a maintenance dose of 200 mg twice daily. Liver function tests should be monitored monthly for any evidence of hepatotoxicity. It is recommended that voriconazole serum concentrations be obtained to ensure appropriate levels of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H12#H12\">",
"     \"Pharmacology of azoles\", section on 'Hepatotoxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H23#H23\">",
"     \"Pharmacology of azoles\", section on 'Voriconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dosing of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    in children is discussed separately. (See",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/60/12234?source=see_link\">",
"     \"Voriconazole: Pediatric drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H417489510\">",
"    <span class=\"h4\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual duration of antifungal therapy is three to six months or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5,69\">",
"     5,69",
"    </a>",
"    ]. In the two randomized trials that have been performed, the duration was 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. We favor a duration of 16 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Omalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential additional therapy that may be beneficial in the treatment of ABPA in children with CF is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    , a humanized monoclonal antibody against IgE. In case reports, seven children with CF and ABPA who were poorly controlled on glucocorticoids or experiencing ABPA exacerbation were treated with omalizumab (300 to 375 mg subcutaneously every two weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. In all seven children, respiratory function improved and glucocorticoid administration was able to be terminated in those receiving glucocorticoids. The duration of follow-up in these reports ranged from 11 weeks to 18 months. However, in another case report of a child with CF and ABPA treated with omalizumab, glucocorticoids were not able to be weaned over a 12-month period while the patient was receiving 300 mg every four weeks of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although much of the described experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    for ABPA has been in patients with CF, there is also interest in evaluating its possible benefit in ABPA patients without CF. In an open-label study that included 16 adult ABPA patients without CF, use of omalizumab for one year was associated with a marked decrease in the number of asthma exacerbations and in oral glucocorticoid dose compared with the year prior to starting omalizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proof of efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    in the treatment of ABPA in those with and without CF await more definitive clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6530443\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled about avoiding exposures to potential environmental sources of Aspergillus.",
"   </p>",
"   <p>",
"    Immunotherapy with fungal allergens has not been evaluated in high-quality studies. Evidence to support the initiation of fungal immunotherapy for the treatment of ABPA is lacking, although patients already receiving immunotherapy for the treatment of other allergic disorders may continue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history, progression between stages, remission, and recurrences of ABPA are not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/24\">",
"     24",
"    </a>",
"    ]. The general teaching is that treatment in the earlier stages is important to try to prevent the development of bronchiectasis or pulmonary fibrosis and that stage V disease carries a worse prognosis. However, progression through these stages is assumed and has not been clearly established. There are cases of pulmonary fibrosis in patients with few preceding episodes or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33545/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/31/41457?source=see_link\">",
"       \"Patient information: Allergic bronchopulmonary aspergillosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction of the airways that occurs when bronchi become colonized by Aspergillus species. ABPA may also develop in patients with cystic fibrosis. Repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspergillus colonization of the asthmatic airway leads to vigorous IgE- and IgG-mediated immune responses superimposed on the asthmatic milieu. Proteolytic enzymes and mycotoxins released by fungi, in concert with Th2-mediated eosinophilic inflammation and IL-8 mediated neutrophilic inflammation, may result in airway damage and central bronchiectasis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ABPA is characterized pathologically by mucoid impaction of the bronchi, eosinophilic pneumonia, and bronchocentric granulomatosis in addition to the histologic features of asthma. Septated hyphae with acute dichotomous branching may be seen in the mucus-filled bronchial lumen, but fungi do not invade the mucosa. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical picture of ABPA is dominated by asthma complicated by recurrent episodes of bronchial obstruction, fever, malaise, expectoration of brownish mucus plugs, peripheral blood eosinophilia, and, at times, hemoptysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with asthma, a staging system for ABPA has been developed to categorize the differing presentations of ABPA (",
"      <a class=\"graphic graphic_table graphicRef76368 \" href=\"mobipreview.htm?28/1/28699\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Staging system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no individual test to establish the diagnosis of ABPA. The diagnosis is usually confirmed by use of clinical, radiographic, and immunologic criteria. The major diagnostic features of classic ABPA include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A history of asthma",
"     </li>",
"     <li>",
"      Immediate skin test reactivity to Aspergillus antigens",
"     </li>",
"     <li>",
"      Precipitating serum antibodies to A. fumigatus",
"     </li>",
"     <li>",
"      Serum total IgE concentration &gt;417",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (&gt;1000",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Peripheral blood eosinophilia",
"      <span class=\"nowrap\">",
"       &gt;500/mm(3)",
"      </span>",
"     </li>",
"     <li>",
"      Lung infiltrates on chest x-ray or chest high-resolution CT",
"     </li>",
"     <li>",
"      Central bronchiectasis on chest CT",
"     </li>",
"     <li>",
"      Elevated specific serum IgE and IgG to A. fumigatus",
"      <br/>",
"      <br/>",
"      The use of these features for establishing the diagnosis is discussed above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A skin prick test should be the first step in an asthmatic being evaluated for ABPA. A negative prick skin test followed by negative intradermal reactivity to Aspergillus virtually excludes ABPA from consideration. If the prick test is positive, serum total IgE and precipitins to Aspergillus should be assayed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of ABPA aims to control episodes of acute inflammation and to limit progressive lung injury. Glucocorticoids are most commonly used, although there is increasing evidence of benefit from combined therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An acute flare (stage I) or recurrent exacerbation (stage III) of ABPA is treated with 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for 14 days followed by conversion to an every other day regimen and a slow taper over three to six months. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stage II disease (remission) and stage V disease (fibrotic lung disease) do not warrant glucocorticoid treatment. Stage IV disease (glucocorticoid-dependent asthma) is present when a patient cannot discontinue glucocorticoids without a recrudescence of asthma symptoms. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      for 16 weeks in all patients who require substantial doses of glucocorticoids, with the goal of enabling a reduction in the glucocorticoid dose. We also suggest itraconazole or voriconazole in patients with relapsed ABPA. (See",
"      <a class=\"local\" href=\"#H417489496\">",
"       'Approach to antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/1\">",
"      Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/2\">",
"      Zander DS. Allergic bronchopulmonary aspergillosis: an overview. Arch Pathol Lab Med 2005; 129:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/3\">",
"      Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/4\">",
"      Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/5\">",
"      Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/6\">",
"      Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med 2009; 30:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/7\">",
"      Beaumont F, Kauffman HF, de Monchy JG, et al. Volumetric aerobiological survey of conidial fungi in the North-East Netherlands. II. Comparison of aerobiological data and skin tests with mould extracts in an asthmatic population. Allergy 1985; 40:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/8\">",
"      Greenberger PA, Smith LJ, Hsu CC, et al. Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE. J Allergy Clin Immunol 1988; 82:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/9\">",
"      Kauffman HF, Tomee JF, van der Werf TS, et al. Review of fungus-induced asthmatic reactions. Am J Respir Crit Care Med 1995; 151:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/10\">",
"      Chauhan, B, Knutsen, AP, Hutcheson, PS, et al. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. J Clin Invest 1996; 97:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/11\">",
"      Kreindler JL, Steele C, Nguyen N, et al. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J Clin Invest 2010; 120:3242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/12\">",
"      Gibson PG, Wark PA, Simpson JL, et al. Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 2003; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/13\">",
"      Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis 2009; 13:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/14\">",
"      Patterson R, Greenberger PA, Radin RC, Roberts M. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982; 96:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/15\">",
"      Buckingham SJ, Hansell DM. Aspergillus in the lung: diverse and coincident forms. Eur Radiol 2003; 13:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/16\">",
"      Reiff DB, Wells AU, Carr DH, et al. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/17\">",
"      Johkoh T, M&uuml;ller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. Radiology 2000; 216:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/18\">",
"      Neeld DA, Goodman LR, Gurney JW, et al. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1990; 142:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/19\">",
"      Paganin F, Trussard V, Seneterre E, et al. Chest radiography and high resolution computed tomography of the lungs in asthma. Am Rev Respir Dis 1992; 146:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/20\">",
"      Ward S, Heyneman L, Lee MJ, et al. Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients. AJR Am J Roentgenol 1999; 173:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/21\">",
"      Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest 2007; 132:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/22\">",
"      Malo JL, Longbottom J, Mitchell J, et al. Studies in chronic allergic bronchopulmonary aspergillosis. 3. Immunological findings. Thorax 1977; 32:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/23\">",
"      Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986; 56:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/24\">",
"      Vlahakis NE, Aksamit TR. Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc 2001; 76:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/25\">",
"      Angus RM, Davies ML, Cowan MD, et al. Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus. Thorax 1994; 49:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/26\">",
"      Glancy JJ, Elder JL, McAleer R. Allergic bronchopulmonary fungal disease without clinical asthma. Thorax 1981; 36:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/27\">",
"      Berkin KE, Vernon DR, Kerr JW. Lung collapse caused by allergic bronchopulmonary aspergillosis in non-asthmatic patients. Br Med J (Clin Res Ed) 1982; 285:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/28\">",
"      Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 1988; 81:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/29\">",
"      Schwartz HJ, Citron KM, Chester EH, et al. A comparison of the prevalence of sensitization to Aspergillus antigens among asthmatics in Cleveland and London. J Allergy Clin Immunol 1978; 62:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/30\">",
"      Schwartz HJ, Greenberger PA. The prevalence of allergic bronchopulmonary aspergillosis in patients with asthma, determined by serologic and radiologic criteria in patients at risk. J Lab Clin Med 1991; 117:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/31\">",
"      Basich JE, Graves TS, Baz MN, et al. Allergic bronchopulmonary aspergillosis in corticosteroid-dependent asthmatics. J Allergy Clin Immunol 1981; 68:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/32\">",
"      Eaton T, Garrett J, Milne D, et al. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. Chest 2000; 118:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/33\">",
"      Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/34\">",
"      Bahous J, Malo JL, Paquin R, et al. Allergic bronchopulmonary aspergillosis and sensitization to Aspergillus fumigatus in chronic bronchiectasis in adults. Clin Allergy 1985; 15:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/35\">",
"      Faux JA, Shale DJ, Lane DJ. Precipitins and specific IgG antibody to Aspergillus fumigatus in a chest unit population. Thorax 1992; 47:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/36\">",
"      Simmonds EJ, Littlewood JM, Evans EG. Cystic fibrosis and allergic bronchopulmonary aspergillosis. Arch Dis Child 1990; 65:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/37\">",
"      Hiller EJ. Aspergillosis. J R Soc Med 1992; 85 Suppl 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/38\">",
"      Laufer P, Fink JN, Bruns WT, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 1984; 73:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/39\">",
"      Knutsen AP, Hutcheson PS, Mueller KR, Slavin RG. Serum immunoglobulins E and G anti-Aspergillus fumigatus antibody in patients with cystic fibrosis who have allergic bronchopulmonary aspergillosis. J Lab Clin Med 1990; 116:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/40\">",
"      Becker JW, Burke W, McDonald G, et al. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996; 109:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/41\">",
"      Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999; 115:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/42\">",
"      Geller DE, Kaplowitz H, Light MJ, Colin AA. Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Chest 1999; 116:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/43\">",
"      Fitzsimons EJ, Aris R, Patterson R. Recurrence of allergic bronchopulmonary aspergillosis in the posttransplant lungs of a cystic fibrosis patient. Chest 1997; 112:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/44\">",
"      CAMPBELL MJ, CLAYTON YM. BRONCHOPULMONARY ASPERGILLOSIS. A CORRELATION OF THE CLINICAL AND LABORATORY FINDINGS IN 272 PATIENTS INVESTIGATED FOR BRONCHOPULMONARY ASPERGILLOSIS. Am Rev Respir Dis 1964; 89:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/45\">",
"      McCarthy DS, Pepys J. Allergic broncho-pulmonary aspergillosis. Clinical immunology. 2. Skin, nasal and bronchial tests. Clin Allergy 1971; 1:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/46\">",
"      Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 1977; 86:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/47\">",
"      Chapman BJ, Capewell S, Gibson R, et al. Pulmonary eosinophilia with and without allergic bronchopulmonary aspergillosis. Thorax 1989; 44:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/48\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/49\">",
"      Breslin AB, Jenkins CR. Experience with allergic bronchopulmonary aspergillosis: some unusual features. Clin Allergy 1984; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/50\">",
"      Golbert TM, Patterson R. Pulmonary allergic aspergillosis. Ann Intern Med 1970; 72:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/51\">",
"      Ricketti AJ, Greenberger PA, Patterson R. Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1984; 74:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/52\">",
"      Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir Med 2010; 104:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/53\">",
"      Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994; 49:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/54\">",
"      Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/55\">",
"      Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; :CD001108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/56\">",
"      Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/57\">",
"      Pasqualotto AC, Powell G, Niven R, Denning DW. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 2009; 14:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/58\">",
"      Salez F, Brichet A, Desurmont S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/59\">",
"      Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/60\">",
"      Varis T, Kaukonen KM, Kivist&ouml; KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998; 64:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/61\">",
"      Bolland MJ, Bagg W, Thomas MG, et al. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/62\">",
"      Woods DR, Arun CS, Corris PA, Perros P. Cushing's syndrome without excess cortisol. BMJ 2006; 332:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/63\">",
"      Parmar JS, Howell T, Kelly J, Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002; 57:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/64\">",
"      Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/65\">",
"      Wong J, Black P. Acute adrenal insufficiency associated with high dose inhaled steroids. BMJ 1992; 304:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/66\">",
"      Erwin GE, Fitzgerald JE. Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole. J Asthma 2007; 44:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/67\">",
"      Glackin L, Leen G, Elnazir B, Greally P. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009; 102:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/68\">",
"      Laoudi Y, Paolini JB, Grimfed A, Just J. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 31:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/69\">",
"      Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/70\">",
"      Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008; 43:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/71\">",
"      van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/72\">",
"      Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008; 43:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/73\">",
"      Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009; 44:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/74\">",
"      Brinkmann F, Schwerk N, Hansen G, Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010; 65:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33545/abstract/75\">",
"      Tillie-Leblond I, Germaud P, Leroyer C, et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011; 66:1254.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2419 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33545=[""].join("\n");
var outline_f32_48_33545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - High resolution computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ABPA versus conventional asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ABPA in cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ABPA and pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ABPA and bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H417489496\">",
"      - Approach to antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H417489503\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H417489578\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H417489510\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Omalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6530443\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2419\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2419|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/38/3682\" title=\"diagnostic image 1\">",
"      Central bronchiectasis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2419|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/1/28699\" title=\"table 1\">",
"      Stages of ABPA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44484?source=related_link\">",
"      Bronchocentric granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/31/41457?source=related_link\">",
"      Patient information: Allergic bronchopulmonary aspergillosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/25/11668?source=related_link\">",
"      Pulmonary manifestations of ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25689?source=related_link\">",
"      The role of fungi (molds) in human disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31529?source=related_link\">",
"      Treatment of chronic pulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2532?source=related_link\">",
"      Tropical filarial pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/60/12234?source=related_link\">",
"      Voriconazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_48_33546="Predictors of survival in heart failure due to systolic dysfunction";
var content_f32_48_33546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Predictors of survival in heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/48/33546/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/48/33546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a common clinical syndrome associated with a mortality rate that varies with the severity of disease and the administration of appropriate medical therapy. The following discussion will review the major clinical and laboratory predictors of survival in patients with HF due to systolic dysfunction. Other than determining eligibility for cardiac transplantation, the clinical value of estimating prognosis is unclear since almost all patients with HF are treated with similar drugs.",
"   </p>",
"   <p>",
"    The overall prognosis of HF and the predictors in patients with diastolic dysfunction are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link\">",
"     \"Prognosis of heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAJOR PREDICTORS OF SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major challenge in the management of HF is the accurate identification of those patients who have a poor prognosis and who would therefore be most likely to benefit from intensive medical therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac transplantation. Many univariate predictors of reduced survival have been identified in HF (",
"    <a class=\"graphic graphic_table graphicRef75049 \" href=\"mobipreview.htm?39/39/40572\">",
"     table 1",
"    </a>",
"    ). Identification of these factors should be part of the initial evaluation of any patient with HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequently used factors for predicting survival in patients with systolic HF, many of which are direct or indirect measures of the severity of cardiac dysfunction, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High New York Heart Association (NYHA) functional class (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reduced left ventricular ejection fraction (LVEF) and reduced cardiac index (CI)",
"     </li>",
"     <li>",
"      Concomitant diastolic dysfunction, as established by a mitral flow velocity pattern on Doppler echocardiogram",
"     </li>",
"     <li>",
"      Reduced right ventricular function",
"     </li>",
"     <li>",
"      Low peak VO2 with maximal exercise and exercise hemodynamics",
"     </li>",
"     <li>",
"      Markers of reduced tissue perfusion including low mean arterial pressure, renal insufficiency (creatinine clearance &lt;60",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      and an attenuated response to diuretics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lack of hemodynamic improvement with therapy, as indicated by failure to reduce left ventricular (LV) filling pressure and persistence of signs of congestion (orthopnea, jugular venous distension, edema, weight gain, or increased need for diuretics), is also associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these cardiac parameters, comorbid factors and the cause of the HF are important determinants of prognosis. As examples, the prognosis is worse in patients with diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and ischemic cardiomyopathy in which the extent of the coronary artery disease is important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Ventricular tachycardia is also an adverse prognostic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NYHA functional class",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NYHA criteria are most often used to assess the functional class of patients with HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I &mdash; No limitation during ordinary activity",
"     </li>",
"     <li>",
"      Class II &mdash; Slight limitation by shortness of breath",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fatigue during moderate exertion or stress",
"     </li>",
"     <li>",
"      Class III &mdash; Symptoms with minimal exertion that interfere with normal daily activity",
"     </li>",
"     <li>",
"      Class IV &mdash; Inability to carry out any physical activity; these patients typically have marked neurohumoral activation and muscle wasting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prospective studies evaluating the use of ACE inhibitors have demonstrated a strong relationship between the functional class and mortality (",
"    <a class=\"graphic graphic_figure graphicRef63748 \" href=\"mobipreview.htm?33/28/34253\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings in control groups",
"    <strong>",
"     not",
"    </strong>",
"    receiving an ACE inhibitor can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic patients (class I) have a one and four",
"      <strong>",
"       year",
"      </strong>",
"      mortality rate of 5 and 19 percent (",
"      <a class=\"graphic graphic_figure graphicRef75136 \" href=\"mobipreview.htm?11/15/11517\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with NYHA class II or III HF have a one and four",
"      <strong>",
"       year",
"      </strong>",
"      mortality rate of 15 and 40 percent (",
"      <a class=\"graphic graphic_figure graphicRef70015 \" href=\"mobipreview.htm?10/28/10701\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with NYHA class IV do much worse with 6 and 12",
"      <strong>",
"       month",
"      </strong>",
"      mortality rates of 44 and 64 percent in one large trial (",
"      <a class=\"graphic graphic_figure graphicRef62325 \" href=\"mobipreview.htm?22/61/23517\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations indicate the importance of early treatment of HF in an attempt to slow progression to more severe disease. As an example, the improved outcome in patients treated with an ACE inhibitor is due primarily to better preservation of myocardial function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Left ventricular ejection fraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilated cardiomyopathy is characterized by a variable reduction in LVEF, the assessment of which is probably the most frequently performed cardiac function test in patients with HF. Clinically evident HF due to systolic dysfunction is generally not apparent until the LVEF falls below 35 to 40 percent, as determined by echocardiography or contrast or radionuclide angiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is, however, no predictable relationship between symptoms or exercise tolerance and the LVEF. Some patients are asymptomatic with an LVEF below 20 percent, while others are moribund with an LVEF above 30 percent.",
"   </p>",
"   <p>",
"    In general, survival is shorter in patients with lower LVEFs (",
"    <a class=\"graphic graphic_figure graphicRef54758 \" href=\"mobipreview.htm?27/30/28141\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82195 \" href=\"mobipreview.htm?34/15/35069\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. As an example, the relationship between LVEF and outcome was evaluated in 5010 patients enrolled in the Val-HeFT trial in whom echocardiograms were obtained at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/11\">",
"     11",
"    </a>",
"    ]. Decreasing quartiles of LVEF were associated with increasing all-cause mortality at 23 months. Patients in the first quartile (mean LVEF 35 percent) had a significantly lower mortality rate than those in the fourth quartile (mean LVEF 17 percent) (14 versus 26 percent mortality, risk ratio 0.5). An LVEF below 20 percent is typically associated with poor survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]; some recommend cardiac transplantation in all such patients who are eligible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, relying on only a univariate predictor such as the LVEF to estimate survival is not very sensitive in the individual patient. As mentioned above, large trials have demonstrated that patients with NYHA class II or III HF have a worse prognosis than those who are asymptomatic. Despite the difference in outcome, the difference in mean LVEF between asymptomatic and symptomatic patients in these trials was small&mdash;28 to 31 percent in asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/8,17\">",
"     8,17",
"    </a>",
"    ] versus 25 percent in patients with moderate symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Concomitant diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant diastolic dysfunction is associated with decreased survival among patients with HF and a reduced LVEF. Studies evaluating diastolic compliance with Doppler echocardiography have shown that a reduction in mitral flow velocity (as determined by a short deceleration time &le;115 msec, and an early-to-late flow velocity or",
"    <span class=\"nowrap\">",
"     E/A",
"    </span>",
"    ratio &gt;1) is a powerful independent predictor of mortality or the need for transplantation among patients with HF (",
"    <a class=\"graphic graphic_waveform graphicRef72146 \" href=\"mobipreview.htm?31/45/32470\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55685 \" href=\"mobipreview.htm?19/2/19501\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=see_link\">",
"     \"Echocardiographic evaluation of left ventricular diastolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic value of abnormal mitral flow velocity may be enhanced by assessing changes in this parameter during alterations in loading conditions. This was illustrated in a report of 173 patients with chronic HF (53 percent ischemic cardiomyopathy) which measured the outcomes at 17 months in four subgroups that were distinguished by differences in changes in mitral valve flow velocity observed during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    infusion (resulting in a reversible or nonreversible restrictive pattern) and passive leg lifting (resulting in a stable or nonstable nonrestrictive pattern) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An irreversible restrictive pattern was associated with a 51 percent cardiac event rate (cardiac death or urgent transplantation)",
"     </li>",
"     <li>",
"      An unstable nonrestrictive pattern was associated with a 33 percent cardiac event rate",
"     </li>",
"     <li>",
"      A reversible restrictive pattern was associated with a 19 percent cardiac event rate",
"     </li>",
"     <li>",
"      A stable nonrestrictive pattern was associated with a 6 percent cardiac event rate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for these observations comes from a study of 144 patients with HF (76 percent ischemic cardiomyopathy) who initially had a restrictive pattern on Doppler echocardiography; this test was repeated after six months of optimal medical therapy that included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , diuretics, an ACE inhibitor, and a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/21\">",
"     21",
"    </a>",
"    ]. At a mean follow-up of 26 months, patients with reversal of the restrictive pattern at six months had a lower cardiac mortality (11 versus 37 percent) and a lesser likelihood of being admitted to the hospital for worsening of HF (11 versus 54 percent) than those with persistence of the restrictive pattern.",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress on a restrictive pattern also appears to have prognostic value. This was illustrated in a review of 69 patients with ischemic dilated cardiomyopathy: 42 had a restrictive left ventricular filling at rest, which reverted to a nonrestrictive pattern in 24 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients with a persistent restrictive pattern had a significantly lower rate of survival at three years compared to those with a reversible restrictive pattern or those with a nonrestrictive pattern at rest (49 versus 79 and 89 percent, respectively). Persistence of the restrictive pattern was associated with a marked rise in left atrial pressure and a markedly attenuated inotropic response.",
"   </p>",
"   <p>",
"    The presence of a restrictive pattern on Doppler echocardiogram also adds incremental predictive value to peak VO2, a measure of functional capacity, for establishing the prognosis in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other indicators of elevated LV filling pressure due to diastolic dysfunction and a restrictive pattern include a high pulmonary capillary wedge pressure (PCWP) and increased lung uptake of thallium (high thallium",
"    <span class=\"nowrap\">",
"     lung/heart",
"    </span>",
"    ratio) on stress imaging. The latter finding may have incremental prognostic value over clinical and other imaging findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Right ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right ventricular systolic dysfunction also may contribute to prognosis in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. Echocardiographic measurements of reduced right ventricular function include a reduction in right ventricular ejection fraction (RVEF), right ventricular enlargement, and tricuspid regurgitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15562?source=see_link\">",
"     \"Echocardiographic recognition of cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognostic importance of right ventricular function was illustrated in a series of 205 patients with class II or III HF; the RVEF was an independent predictor of one and two year survival and event-free cardiac survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/28\">",
"     28",
"    </a>",
"    ]. At two years, the event-free survival rates from cardiovascular mortality and urgent transplantation for those with an RVEF &ge;35 percent, &ge;25 to &lt;35 percent, and &lt;25 percent were 93, 77, and 59 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef54666 \" href=\"mobipreview.htm?43/14/44269\">",
"     figure 8",
"    </a>",
"    ). A similar adverse effect on outcome is seen with right ventricular enlargement, which is often associated with more severe tricuspid regurgitation (",
"    <a class=\"graphic graphic_figure graphicRef52318 \" href=\"mobipreview.htm?20/20/20813\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/26\">",
"     26",
"    </a>",
"    ], an abnormality that itself is associated with a worse prognosis (",
"    <a class=\"graphic graphic_figure graphicRef51483 \" href=\"mobipreview.htm?38/25/39325\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary artery pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired right ventricular contractility in patients with left-sided HF may be due to primary myocardial disease or to poor LV function with an elevated pulmonary artery pressure. Right ventricular dysfunction appears to be of prognostic importance only when associated with elevated pulmonary artery pressure; assessment of right ventricular function in patients with normal pulmonary artery pressure does not improve risk stratification (",
"    <a class=\"graphic graphic_figure graphicRef56623 \" href=\"mobipreview.htm?24/44/25294\">",
"     figure 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of an elevated pulmonary artery pressure was further addressed in a prospective study of 1134 patients with a new cardiomyopathy who underwent right heart catheterization and endomyocardial biopsy and were followed for 4.4 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/31\">",
"     31",
"    </a>",
"    ]. With a multivariate model, mean pulmonary artery pressure was the most important hemodynamic predictor of death, especially in the 93 patients (8.3 percent) with a diagnosis of myocarditis. For each 5 mmHg increase in baseline mean pulmonary artery pressure, the mortality in those with and without myocarditis increased with a relative hazard of 1.85 and 1.23, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other echocardiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the LVEF and diastolic and right ventricular function, a number of other echocardiographic findings have been associated with prognosis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LV dilatation or an LV end-diastolic volume index &gt;120",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/11,32\">",
"       11,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A restrictive mitral filling pattern and an LV systolic diameter index &gt;2.75",
"      <span class=\"nowrap\">",
"       cm/m2,",
"      </span>",
"      particularly if associated with a QRS duration &gt;144 msec [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased LV mass &ge;298 g [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased left atrial size (dimension &ge;4.17 or volume index &gt;68.5",
"      <span class=\"nowrap\">",
"       ml/m2",
"      </span>",
"      or 63",
"      <span class=\"nowrap\">",
"       ml/m2)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef77947 \" href=\"mobipreview.htm?23/32/24078\">",
"       figure 12",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/12,34,35\">",
"       12,34,35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Augmentation of LVEF during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography is also of prognostic importance in patients with an idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9378047\">",
"    <span class=\"h2\">",
"     QRS prolongation and LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HF, a QRS duration &ge;120 msec is common and is associated with a significant increase in mortality. As an example, in a retrospective analysis from the EVEREST trial, 45 percent of 2962 enrolled patients hospitalized for HF had a QRS duration &ge; 120 msec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/38\">",
"     38",
"    </a>",
"    ]. QRS prolongation was associated with increased all-cause mortality (adjusted hazard ratio 1.28, 95% CI 1.10-1.49) at a median of 9.9 months follow-up.",
"   </p>",
"   <p>",
"    The worse outcomes with QRS prolongation have been attributed in part to ventricular dyssynchrony resulting from the conduction defect. Many such patients are treated with cardiac resynchronization (biventricular pacing), since randomized trials have shown a clear survival benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Left bundle branch block (LBBB) on ECG, which is seen in 25 percent of patients with HF, is associated with increased all-cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] and sudden death mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/39\">",
"     39",
"    </a>",
"    ]. In analyses including LVEF, LBBB was an independent risk predictor of mortality in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/39\">",
"     39",
"    </a>",
"    ] but not others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/40\">",
"     40",
"    </a>",
"    ], suggesting that LBBB may be a marker for but not a direct cause of increased mortality risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because exercise requires an increase in cardiac work, evaluation of exercise capacity and cardiac function during exercise are effective ways of demonstrating the severity of HF. Several exercise parameters including peak VO2, six-minute walk distance, and exercise hemodynamics have been correlated with patient survival. The predictive value of exercise parameters is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurohumoral activation and heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low output state in HF results in multiple physiologic responses due to increased release of neurohormones. These include hyponatremia and elevated plasma concentrations of norepinephrine, brain natriuretic peptide (BNP), renin, endothelin-1, and big endothelin-1 (",
"    <a class=\"graphic graphic_figure graphicRef58128 graphicRef55554 graphicRef59265 graphicRef78693 graphicRef58488 \" href=\"mobipreview.htm?8/54/9061\">",
"     figure 13A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, only the plasma sodium and BNP concentrations are measured clinically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Otherwise unexplained hyponatremia is a poor prognostic finding. In a study of patients with severe HF, for example, patients with a plasma sodium concentration less than 137",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      had more than a 50 percent reduction in median survival (164 versus 373 days) (",
"      <a class=\"graphic graphic_figure graphicRef55554 \" href=\"mobipreview.htm?29/6/29805\">",
"       figure 13B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"       \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevations in plasma BNP predict reduced survival in patients with chronic and acute decompensated HF (",
"      <a class=\"graphic graphic_figure graphicRef78693 \" href=\"mobipreview.htm?35/56/36750\">",
"       figure 13D",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/43-45,48-52\">",
"       43-45,48-52",
"      </a>",
"      ]. They also predict an increased risk for sudden death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link&amp;anchor=H19#H19\">",
"       \"Natriuretic peptide measurement in heart failure\", section on 'Prognosis of HF'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An elevated heart rate, probably reflecting activation of the sympathetic nervous system, is also associated with a worse outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/54-56\">",
"       54-56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=see_link\">",
"       \"Sinus tachycardia\"",
"      </a>",
"      .) In an analysis of the placebo group in the BEAUTIFUL trial, cardiovascular outcomes were compared in 2693 patients with heart rates of &ge;70",
"      <span class=\"nowrap\">",
"       beats/minute",
"      </span>",
"      (bpm) and 2745 patients with heart rates &lt;70 bpm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/56\">",
"       56",
"      </a>",
"      ]. All patients had coronary artery disease, LVEF &lt;40 percent and resting heart rate of &ge;60 bpm. For every 5 bpm increase there were significant increases in cardiovascular death (8 percent), admission to hospital for HF (16 percent), and coronary revascularization (8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Signs of reduced tissue perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical signs of reduced tissue perfusion are indicative of more severe disease and a worse prognosis. These include a low mean arterial blood pressure, renal insufficiency, an attenuated response to diuretics, and lack of hemodynamic improvement with therapy, as indicated by failure to reduce LV filling pressure, are also associated with a poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/57-62\">",
"     57-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Low blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low systolic, diastolic, and mean arterial blood pressures have all been associated with increased mortality in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/57,63\">",
"     57,63",
"    </a>",
"    ]. The mean arterial blood pressure can be estimated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Mean arterial pressure &nbsp;= &nbsp;(systolic blood pressure &nbsp;+ &nbsp;[2 &nbsp;x &nbsp;diastolic blood pressure] &nbsp;&divide; &nbsp;3)",
"   </p>",
"   <p>",
"    In the SOLVD trial, each 10 mmHg decrease in baseline mean arterial pressure was associated with a 14 percent increase in total and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/57\">",
"     57",
"    </a>",
"    ], while a post-hoc analysis from the DIG study database found that mortality was highest in patients with systolic blood pressure &lt;100 mmHg and diastolic blood pressure &lt;60 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Reduced glomerular filtration rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of important interactions between heart disease and kidney disease. The interaction is bidirectional as heart disease can affect renal function and renal disease can affect cardiac function. As an example, reduced renal function is associated with increased mortality in patients with heart failure (HF), as will be discussed below. On the other hand, patients with chronic kidney disease have an increased risk of both atherosclerotic cardiovascular disease and heart failure, and cardiovascular disease is responsible for up to 50 percent of deaths in patients with renal failure. In addition, acute or chronic dysfunction of the heart or kidneys can induce acute or chronic dysfunction in the other organ. The term cardiorenal syndrome has been applied to these interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=see_link\">",
"     \"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reduced glomerular filtration rate (GFR) is associated with increased mortality risk in patients with HF. The magnitude of the effect can be illustrated by the findings in a systematic review of 16 studies with over 80,000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/64\">",
"     64",
"    </a>",
"    ]. The mortality rate at a follow-up of one year or more was 24 percent in those with a normal GFR compared to 38 and 51 percent in patients with mild and moderate to severe reductions in GFR, respectively (adjusted hazard ratio 1.6 and 2.3). An elevated blood urea nitrogen (blood urea) is also associated with increased mortality, an effect that may be in part independent of the GFR. Optimal management of these patients is not well defined. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=see_link&amp;anchor=H28486377#H28486377\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\", section on 'Reduced GFR and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reduced myocardial blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with idiopathic cardiomyopathy, reduced myocardial blood flow, as assessed by positron emission tomography at rest and after intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , is an independent predictor of subsequent cardiac events (death or the development or progression of HF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/65\">",
"     65",
"    </a>",
"    ]. This association is independent of other clinical and functional variables. Because of the decreased availability and higher cost of this test, it is unclear what its clinical role may be.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of AF in patients with HF varies from 10 to 30 percent, depending upon the population studied. There are conflicting data as to whether AF is an independent predictor of increased mortality in patients with HF; data from the SOLVD trials and the Framingham Heart Study suggest such an increase, while data from the V-HeFT I and II trials do not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link&amp;anchor=H5#H5\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that there is an association between anemia and increased mortality in patients with HF, although it is unclear whether anemia is responsible for worse outcomes or merely a marker for more severe HF. At least one small study has suggested that erythropoietin therapy may reduce mortality in anemic HF patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/66\">",
"     66",
"    </a>",
"    ]. However, benefit has not been proven and there is the potential for harm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1705?source=see_link&amp;anchor=H15#H15\">",
"     \"Impact of anemia in patients with heart failure\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CHARM trials evaluated the role of an angiotensin II receptor blocker in the treatment HF due to both systolic and diastolic dysfunction. A retrospective analysis of 7599 patients from these trials assessed the prognostic significance of approximately 50 baseline variables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to age and LVEF, diabetes was among the most powerful independent predictors of mortality and HF hospitalizations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREDICTIVE MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are drawbacks to using any individual predictor as a guide to therapy. Although the above factors correlate with survival on a statistical basis in a large population, their ability to predict survival in individual patients is limited. As a result, a number of retrospective analyses have developed predictive models that utilize multiple indicators to generate a more accurate estimate of prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis of heart failure\", section on 'Predictive models'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER PREDICTORS OF SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of other findings that have been associated with the outcome of patients with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     S3 gallop and jugular venous pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an S3 gallop",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated jugular venous pressure appear to have prognostic significance. In a review of 2569 patients from the SOLVD treatment trial, 24 percent had an S3 gallop and 11.8 percent had an elevated jugular venous pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/67\">",
"     67",
"    </a>",
"    ]. After adjusting for other markers of disease severity, an S3 gallop and elevated jugular venous pressure were each associated with an increased risk of hospitalization for HF (relative risk 1.42 and 1.32, respectively) and of death from pump failure (relative risk 1.40 and 1.37). One limitation to these observations is the operator-dependence for the detection of these physical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Functional MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HF often develop functional or secondary mitral regurgitation (MR) due to annular enlargement secondary to LV dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papillary displacement due to LV remodeling. Although data are limited, patients with moderate to severe MR appear to have a worse prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in serum C-reactive protein (CRP) are associated with worse outcomes in patients with atherosclerotic cardiovascular disease. Data in heart failure have been limited, but suggests an association between CRP and outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible predictive value of serum CRP was addressed in a post hoc analysis from the Val-HeFT trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    therapy in HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/68\">",
"     68",
"    </a>",
"    ]. The median serum CRP was higher in patients with HF compared to the general population and the cumulative likelihood of death or a first morbid event increased progressively with quartiles of serum CRP (eg, the adjusted hazard ratio for mortality was 1.53 in the highest compared to the lowest quartile for serum CRP). At one year, serum CRP was stable in the placebo group but fell in patients receiving valsartan who were not receiving an ACE inhibitor but not in those who were.",
"   </p>",
"   <p>",
"    Similar findings were noted in a review of 546 consecutive patients (mean age 56) with stable systolic HF (mean LVEF 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/69\">",
"     69",
"    </a>",
"    ]. Almost all patients were treated with ACE inhibitors and beta blockers. A serum CRP &gt;3",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    was an independent predictor of cardiovascular mortality (hazard ratio 1.78). This effect, which was only seen in patients with ischemic cardiomyopathy, was independent of other major predictors, such as peak VO2 and serum BNP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Heart rate variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced heart rate variability, which indicates increased sympathetic or reduced parasympathetic tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/71-73\">",
"     71-73",
"    </a>",
"    ], is associated with a worse prognosis in patients with HF. In one study of 433 patients, the annual mortality for those with standard deviation of normal RR intervals (SDNN) of &gt;100 msec, 50 to 100 msec, and &lt;50 msec was 5.5, 12.7, and 51.4 percent, respectively; values below 100 msec indicate absence of heart rate variability (",
"    <a class=\"graphic graphic_figure graphicRef62928 \" href=\"mobipreview.htm?31/59/32701\">",
"     figure 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Planar QRS-T angle",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report of 455 patients with nonischemic cardiomyopathy, NYHA class I to III HF, and nonsustained VT or frequent ventricular ectopy, a planar QRS-T angle greater than 90 degrees was a predictor of the composite end point of total mortality, appropriate implantable cardioverter-defibrillator shock, or resuscitated cardiac arrest as well as total mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/74\">",
"     74",
"    </a>",
"    ]. Changes in the QRS-T angle correlated with changes in left ventricular ejection fraction and QRS duration over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Troponins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating troponin levels are a sensitive marker of acute myocardial injury but elevations also occur in a variety of other disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevations in circulating troponin T (TnT) and troponin I (TnI) are predictors of adverse outcomes in hospitalized as well as stable ambulatory patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/52,75-84\">",
"     52,75-84",
"    </a>",
"    ]. Elevations in both troponin and brain natriuretic peptide (BNP) are associated with an increased risk compared to elevations in either measurement alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/52,80,83,84\">",
"     52,80,83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of plasma troponin T is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 4053 patients with chronic HF with LVEF &lt;40 percent enrolled in the Val-HeFT trial, plasma troponin T was detectable in 10.4 percent of the population with the traditional (cTnT) assay and in 92 percent of the population using a highly sensitive assay (hsTnT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/80\">",
"       80",
"      </a>",
"      ]. In models adjusting for other risk factors, both baseline TnT and baseline hsTnT were significantly associated with all-cause mortality and first hospitalization for HF at median two year follow-up. In addition, hsTnT was significantly associated with mortality in the 90 percent of the population with undetectable cTnT by the traditional assay.",
"     </li>",
"     <li>",
"      Baseline cTnI level was an independent predictor of risk of first hospitalization for HF after exclusion of myocardial infarction (per 0.01",
"      <span class=\"nowrap\">",
"       &mu;g/L",
"      </span>",
"      of cTnI, adjusted HR 1.31; 95% CI 1.16 to 1.47) during nine year median follow-up of a population of 1089 70 year old men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Baseline hsTnT level and increases in hsTnT levels were significantly associated with new onset HF and cardiovascular death during 11.8 year median follow-up in a nationwide cohort of 4221 adults &ge; 65 years of age enrolled in the Cardiovascular Health Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/82\">",
"       82",
"      </a>",
"      ]. The addition of baseline hsTNT to clinical risk factors yielded a significant but modest improvement in discrimination of risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small studies have found an association between worsening left ventricular ejection fraction and baseline troponin level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/79\">",
"     79",
"    </a>",
"    ] or persistently elevated troponin levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/76\">",
"     76",
"    </a>",
"    ]. Persistently elevated troponin levels were also associated with higher cardiac event rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/76,81\">",
"     76,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial strain and myocyte death are two related mechanisms that can contribute to the troponin elevations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link&amp;anchor=H16#H16\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Low serum cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the beneficial effect of a low serum cholesterol induced by statin therapy in patients with coronary heart disease, a low serum cholesterol in patients with HF is associated with higher mortality. This issue and the possible role of statin therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24453?source=see_link\">",
"     \"Statin therapy in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated serum uric acid (UA) concentration was associated with an increase in mortality in an evaluation of 112 patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/85\">",
"     85",
"    </a>",
"    ]. These patients formed a derivation sample to identify a threshold value for UA of 9.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (565",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    In a validation sample of 182 patients with HF, those with a serum UA above the threshold value had a much poorer survival rate at four years than those with lower levels (19 versus 79 percent).",
"   </p>",
"   <p>",
"    These observations do not address the issue of whether hyperuricemia is simply a marker for more severe heart disease, since both a low cardiac output and diuretic therapy reduce uric acid excretion. Consistent with a possible causal role is the observation in patients with hyperuricemia and heart failure that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    therapy improves endothelial function and local blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a similar effect has been seen in patients with heart failure without hyperuricemia in association with reduced markers of oxidative stress, suggesting that xanthine oxidase inhibition itself may be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/87\">",
"     87",
"    </a>",
"    ]. Furthermore, in an animal model of HF, long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    therapy improved left ventricular function and prevented left ventricular remodeling, benefits that were associated with a transient reduction in reactive oxygen species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperuricemia has also been evaluated as a risk factor for coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=see_link&amp;anchor=H1265380#H1265380\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Uric acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Weight loss and BMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss in patients with HF (sometimes called \"cardiac cachexia\" if severe) is linked to a poor prognosis. Both increased energy expenditure and decreased energy intake may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=see_link\">",
"     \"Approach to the patient with weight loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an analysis of data on 1929 patients from the SOLVD treatment trial, 39 percent of whom had died by three years, weight loss of 6 percent at eight months was the best threshold value for predicting reduced survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/90\">",
"     90",
"    </a>",
"    ]. This model was then validated using data on 619 patients from the V-HeFT II trial, 30 percent of whom had died at nine months. Weight loss of 6 percent at nine months predicted subsequent survival with a hazard ratio of 1.85.",
"   </p>",
"   <p>",
"    In an analysis of data on 7599 patients with symptomatic HF with a broad range of LVEF from the CHARM clinical trials, 29 percent died by 38 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients with BMI &lt;30",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    had greater mortality than those with BMI between 30 and 34.9",
"    <span class=\"nowrap\">",
"     kg/m2;",
"    </span>",
"    this association was not altered by LVEF. Lower BMI was associated with a greater risk of all-cause death in patients without edema but not in those with edema.",
"   </p>",
"   <p>",
"    High plasma adiponectin levels are an independent predictor of mortality in chronic HF patients with systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Plasma adiponectin levels are negatively associated with BMI, so the elevated adiponectin levels in HF patients may be a marker for wasting.",
"   </p>",
"   <p>",
"    Although obesity is a risk factor for cardiovascular disease, including HF, and mortality, it does not appear to be a risk factor for mortality in HF, despite its association with hypertension, diabetes, and hypercholesterolemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Hypoalbuminemia and liver function abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoalbuminemia is common among patients with HF though its causes have not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. In a study of 1726 systolic HF patients (LVEF 23&plusmn;7 percent) hypoalbuminemia was present in 25 percent and it was a risk factor for one and five year mortality (HR 2.2 for both), even after adjustment for multiple prognostic factors including BMI, left ventricular ejection fraction, and creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/96\">",
"     96",
"    </a>",
"    ]. Hypoalbuminemia was not associated with BMI. Factors in addition to nutritional status, such as hepatic function, hemodilution, and inflammatory state, may contribute to hypoalbuminemia.",
"   </p>",
"   <p>",
"    The predictive value of liver function tests and albumin level was evaluated in 2679 patients including 1594 with impaired LV systolic function (LVEF &le;40 percent) and 1085 with preserved LV function (LVEF &gt;40 percent) enrolled in the CHARM program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/97\">",
"     97",
"    </a>",
"    ]. Hypoalbuminemia was present in 18 percent, elevated alkaline phosphatase in 14 percent, elevated total bilirubin in 13 percent, elevated alanine aminotransferase in 3 percent, and elevated aspartate aminotransferase in 4 percent. Elevated total bilirubin was nearly twice as common among patients with impaired LVEF as compared to those with preserved LVEF (16 versus 9 percent); the prevalences of the other abnormalities were not markedly different between the two LVEF groups. In univariate analysis adjusted for clinical variables, hypoalbuminemia as well as elevated total bilirubin were predictors of outcomes (cardiovascular death or heart failure hospitalization) with median 38 months follow-up. In a multivariable model including all clinical and laboratory predictors, total bilirubin (but not albumin) remained a significant predictor of outcomes (HR 1.1 per 1SD).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, anemia is associated with increased mortality in patients with HF. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Anemia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another independent predictor of morbidity and mortality is an elevated red cell distribution width (RDW) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/98\">",
"     98",
"    </a>",
"    ]. Among 36 laboratory values considered in the CHARM program of chronic heart failure patients (with depressed and preserved LVEF), higher RDW showed the greatest association with morbidity and mortality. This finding was replicated in the Duke Databank, in which higher RDW was strongly associated with all-cause mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link&amp;anchor=H5#H5\">",
"     \"Mean corpuscular volume\", section on 'Red blood cell distribution width'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other hematologic abnormalities have been associated with increased mortality, such as a decreased percentage of lymphocytes, which reflect stress-induced cortisol release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/99\">",
"     99",
"    </a>",
"    ]; a white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;7000/microL",
"    </span>",
"    in ischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/100\">",
"     100",
"    </a>",
"    ]; and an erythrocyte sedimentation rate &ge;15",
"    <span class=\"nowrap\">",
"     mm/h,",
"    </span>",
"    which reflects an acute phase response to inflammation or infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Low plasma T3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of plasma T3 (triiodothyronine) concentrations as a prognostic indicator was evaluated in a report of 281 patients with systolic HF, 122 of whom (43 percent) had a plasma total T3 concentration below the lower limit of normal (&le;80",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [1.2",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/102\">",
"     102",
"    </a>",
"    ]. Low plasma T3 was an independent predictor of mortality independent of the LVEF. Whether low plasma T3 is a prognostic marker or contributes to progressive disease is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Cytokines and other markers of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cytokines and other markers of inflammation may be important in the pathogenesis of HF and serum levels may provide prognostic information. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Anabolic hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;An imbalance in anabolic and catabolic forces, favoring catabolism, is present in patients with advanced HF. Deficiencies in anabolic hormones (eg, testosterone, dehydroepiandrosterone, and insulin-like growth factor) are associated with increased morbidity and mortality in the general population of adult men, and may have similar implications in men with HF.",
"   </p>",
"   <p>",
"    This possibility was supported in a study of 208 men with HF, in whom anabolic hormone deficiencies were common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/103\">",
"     103",
"    </a>",
"    ]. At a follow-up of three years, these deficiencies were associated with increased mortality, and mortality rates were further increased among men with multiple hormone deficiencies. It is not known if these deficiencies contributed to the severity of HF, were themselves the result of advanced HF, or if they were simply markers of the severity of general chronic illness. In addition, because anabolic deficiencies are known to be associated with worse outcomes in the general population, it is not known if this finding is uniquely ominous in men with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Albuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Albuminuria may be an adverse prognostic indicator in patients with HF as well as in those with other cardiovascular disease (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Albuminuria (identified by spot urinary albumin to creatinine ratio) was common in the class II to IV HF patients enrolled in the CHARM trials; 30 percent had microalbuminuria and 11 percent had macroalbuminuria. Albuminuria was associated with increased risk of mortality as well as the composite outcome (death from cardiovascular causes or admission to hospital with worsening HF), even after adjustment for other prognostic variables including renal function and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression appears to be both relatively common and associated with a worse prognosis in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/105\">",
"     105",
"    </a>",
"    ]. In one study, major depression was associated with increased mortality at three and six months (odds ratio 2.5 and 2.23, respectively, compared to no depression) and with an increased rate of readmission (odds ratio 1.9 and 3.07, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/106\">",
"     106",
"    </a>",
"    ]. In another report, higher Beck Depression Inventory scores were independently associated with greater increases in mortality starting at about three months and continuing throughout the mean follow-up period of 971 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/107\">",
"     107",
"    </a>",
"    ]. In this cohort depression, but not antidepressant or selective serotonin reuptake inhibitor (SSRI) use was independently associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other psychosocial factors, such as marital quality, also are of prognostic importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/15/23800?source=see_link\">",
"     \"Psychosocial factors in sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials evaluating the effect of psychological interventions on the outcome of depressed patients with HF have not been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     mIBG imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metaiodobenzylguanidine (mIBG) is an analog of norepinephrine (NE) that is taken up into cardiac sympathetic nerve endings in the same manner as NE. This uptake is decreased in HF. Radionuclide scintigraphy using I-123-mIBG correlates with established indices of HF severity, including LVEF, CI, PCWP and peak VO2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/111\">",
"     111",
"    </a>",
"    ]. Findings on mIBG imaging are associated with risk of death or transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/111\">",
"     111",
"    </a>",
"    ], risk of sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/112\">",
"     112",
"    </a>",
"    ] and with the likelihood of benefit from beta blocker therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/113\">",
"     113",
"    </a>",
"    ]. The mIBG imaging parameter with greatest prognostic value has differed among studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/111,113,114\">",
"     111,113,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prospective multicenter ADMIRE-HF study evaluated the predictive value of mIBG imaging in 961 subjects with NYHA functional class II or III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and LVEF &le;35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/48/33546/abstract/115\">",
"     115",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     heart/mediastinal",
"    </span>",
"    uptake ratio",
"    <span class=\"nowrap\">",
"     (H/M)",
"    </span>",
"    on mIBG imaging was compared to time to first occurrence of NYHA functional class progression, potentially life-threatening arrhythmic event (sustained ventricular tachycardia, cardiac arrest, or appropriate ICD discharge), or cardiac death. Twenty five percent of subjects experienced events during median follow-up of 17 months. The two-year event rate was 15 percent for an",
"    <span class=\"nowrap\">",
"     H/M",
"    </span>",
"    &ge; 1.6 as compared to 37 percent for an",
"    <span class=\"nowrap\">",
"     H/M",
"    </span>",
"    &le;1.6. The",
"    <span class=\"nowrap\">",
"     H/M",
"    </span>",
"    was a predictor for each of the individual event categories of HF progression, arrhythmic events and cardiac death (HR 0.48, 0.37, and 0.14, respectively). In a multivariable model,",
"    <span class=\"nowrap\">",
"     H/M,",
"    </span>",
"    LVEF, BNP, and NYHA functional class were independent predictors for time to cardiac events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Sleep disordered breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cheyne-Stokes respiration and sleep apnea are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link&amp;anchor=H7#H7\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF often have one or more of the above univariate predictors of decreased survival despite maximal medical therapy. Routine evaluation to estimate severity should include determination of NYHA class; and echocardiography to measure LVEF, assess diastolic and right ventricular function, and identify other abnormalities such as regional wall motion abnormalities; and measurement of the plasma sodium and creatinine concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than determining eligibility for cardiac transplantation, the clinical value of estimating prognosis is unclear since almost all patients with HF due to systolic dysfunction are treated with similar drugs. Risk models may provide a useful method for integrating several clinical variables to arrive at an estimate of prognosis. However, the predictive value of such models depends upon the clinical characteristics of the population that was studied and the list of variables that were considered for potential inclusion in the model. As a result, the prognosis for some patients may not be accurately reflected by these scores. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=see_link&amp;anchor=H13#H13\">",
"     \"Prognosis of heart failure\", section on 'Predictive models'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/1\">",
"      Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000; 140:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/2\">",
"      Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/3\">",
"      Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/4\">",
"      Alla F, Brian&ccedil;on S, Juilli&egrave;re Y, et al. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J 2000; 139:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/5\">",
"      Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/6\">",
"      Cohn JN, Archibald DG, Francis GS, et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987; 75:IV49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/7\">",
"      Wilson JR, Schwartz JS, Sutton MS, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983; 2:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/8\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/9\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/10\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/11\">",
"      Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004; 43:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/12\">",
"      Qui&ntilde;ones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000; 35:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/13\">",
"      Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994; 90:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/14\">",
"      Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112:3738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/15\">",
"      Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/16\">",
"      Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989; 14:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/17\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/18\">",
"      Pozzoli M, Traversi E, Cioffi G, et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation 1997; 95:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/19\">",
"      Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/20\">",
"      Xie GY, Berk MR, Smith MD, et al. Prognostic value of Doppler transmitral flow patterns in patients with congestive heart failure. J Am Coll Cardiol 1994; 24:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/21\">",
"      Temporelli PL, Corr&agrave; U, Imparato A, et al. Reversible restrictive left ventricular diastolic filling with optimized oral therapy predicts a more favorable prognosis in patients with chronic heart failure. J Am Coll Cardiol 1998; 31:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/22\">",
"      Duncan AM, Lim E, Gibson DG, Henein MY. Effect of dobutamine stress on left ventricular filling in ischemic dilated cardiomyopathy: pathophysiology and prognostic implications. J Am Coll Cardiol 2005; 46:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/23\">",
"      Hansen A, Haass M, Zugck C, et al. Prognostic value of Doppler echocardiographic mitral inflow patterns: implications for risk stratification in patients with chronic congestive heart failure. J Am Coll Cardiol 2001; 37:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/24\">",
"      Marcassa C, Galli M, Baroffio C, et al. Independent and incremental prognostic value of (201)Tl lung uptake at rest in patients with severe postischemic left ventricular dysfunction. Circulation 2000; 102:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/25\">",
"      Juilli&egrave;re Y, Barbier G, Feldmann L, et al. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997; 18:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/26\">",
"      Sun JP, James KB, Yang XS, et al. Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities. Am J Cardiol 1997; 80:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/27\">",
"      Karatasakis GT, Karagounis LA, Kalyvas PA, et al. Prognostic significance of echocardiographically estimated right ventricular shortening in advanced heart failure. Am J Cardiol 1998; 82:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/28\">",
"      de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 1998; 32:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/29\">",
"      Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/30\">",
"      Hung J, Koelling T, Semigran MJ, et al. Usefulness of echocardiographic determined tricuspid regurgitation in predicting event-free survival in severe heart failure secondary to idiopathic-dilated cardiomyopathy or to ischemic cardiomyopathy. Am J Cardiol 1998; 82:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/31\">",
"      Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/32\">",
"      Grayburn PA, Appleton CP, DeMaria AN, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure: the Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2005; 45:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/33\">",
"      Bruch C, Gotzmann M, Stypmann J, et al. Electrocardiography and Doppler echocardiography for risk stratification in patients with chronic heart failure: incremental prognostic value of QRS duration and a restrictive mitral filling pattern. J Am Coll Cardiol 2005; 45:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/34\">",
"      Rossi A, Cicoira M, Zanolla L, et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/35\">",
"      Rossi A, Cicoira M, Bonapace S, et al. Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction. Heart 2007; 93:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/36\">",
"      Ramahi TM, Longo MD, Cadariu AR, et al. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy. Eur Heart J 2001; 22:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/37\">",
"      Pratali L, Picano E, Otasevic P, et al. Prognostic significance of the dobutamine echocardiography test in idiopathic dilated cardiomyopathy. Am J Cardiol 2001; 88:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/38\">",
"      Wang NC, Maggioni AP, Konstam MA, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 2008; 299:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/39\">",
"      Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/40\">",
"      Tabrizi F, Englund A, Rosenqvist M, et al. Influence of left bundle branch block on long-term mortality in a population with heart failure. Eur Heart J 2007; 28:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/41\">",
"      Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/42\">",
"      Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/43\">",
"      Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/44\">",
"      Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/45\">",
"      Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/46\">",
"      Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/47\">",
"      H&uuml;lsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/48\">",
"      de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 2004; 43:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/49\">",
"      Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/50\">",
"      Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007; 49:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/51\">",
"      Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/52\">",
"      Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007; 116:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/53\">",
"      Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/54\">",
"      Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multic&eacute;ntricos en Argentina. J Am Coll Cardiol 1997; 29:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/55\">",
"      Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/56\">",
"      Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/57\">",
"      Domanski MJ, Mitchell GF, Norman JE, et al. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/58\">",
"      Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/59\">",
"      Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/60\">",
"      Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/61\">",
"      Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 1997; 80:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/62\">",
"      Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/63\">",
"      Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006; 151:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/64\">",
"      Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/65\">",
"      Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002; 105:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/66\">",
"      Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/67\">",
"      Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/68\">",
"      Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/69\">",
"      Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J 2005; 26:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/70\">",
"      Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006; 151:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/71\">",
"      Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/72\">",
"      Ho KK, Moody GB, Peng CK, et al. Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. Circulation 1997; 96:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/73\">",
"      Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 79:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/74\">",
"      Pavri BB, Hillis MB, Subacius H, et al. Prognostic value and temporal behavior of the planar QRS-T angle in patients with nonischemic cardiomyopathy. Circulation 2008; 117:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/75\">",
"      You JJ, Austin PC, Alter DA, et al. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J 2007; 153:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/76\">",
"      Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/77\">",
"      Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004; 110:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/78\">",
"      Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/79\">",
"      Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/80\">",
"      Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/81\">",
"      Miller WL, Hartman KA, Burritt MF, et al. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009; 54:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/82\">",
"      deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010; 304:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/83\">",
"      Pascual-Figal DA, Manzano-Fern&aacute;ndez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011; 13:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/84\">",
"      Sundstr&ouml;m J, Ingelsson E, Berglund L, et al. Cardiac troponin-I and risk of heart failure: a community-based cohort study. Eur Heart J 2009; 30:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/85\">",
"      Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/86\">",
"      Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/87\">",
"      Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/88\">",
"      Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005; 26:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/89\">",
"      Aquilani R, Opasich C, Verri M, et al. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 2003; 42:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/90\">",
"      Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/91\">",
"      Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007; 116:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/92\">",
"      Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/93\">",
"      Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/94\">",
"      Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/95\">",
"      Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 2007; 153:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/96\">",
"      Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/97\">",
"      Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/98\">",
"      Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/99\">",
"      Ommen SR, Hodge DO, Rodeheffer RJ, et al. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation 1998; 97:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/100\">",
"      Cooper HA, Exner DV, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1999; 84:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/101\">",
"      Sharma R, Rauchhaus M, Ponikowski PP, et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000; 36:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/102\">",
"      Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 2005; 118:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/103\">",
"      Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006; 114:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/104\">",
"      Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/105\">",
"      Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/106\">",
"      Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/107\">",
"      Jiang W, Kuchibhatla M, Clary GL, et al. Relationship between depressive symptoms and long-term mortality in patients with heart failure. Am Heart J 2007; 154:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/108\">",
"      O'Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008; 168:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/109\">",
"      Coyne JC, Rohrbaugh MJ, Shoham V, et al. Prognostic importance of marital quality for survival of congestive heart failure. Am J Cardiol 2001; 88:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/110\">",
"      Lane DA, Chong AY, Lip GY. Psychological interventions for depression in heart failure. Cochrane Database Syst Rev 2005; :CD003329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/111\">",
"      Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999; 33:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/112\">",
"      Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009; 53:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/113\">",
"      Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/114\">",
"      Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003; 41:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/48/33546/abstract/115\">",
"      Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010; 55:2212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3477 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B3B70EFBF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33546=[""].join("\n");
var outline_f32_48_33546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAJOR PREDICTORS OF SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NYHA functional class",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Left ventricular ejection fraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Concomitant diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Right ventricular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary artery pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other echocardiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9378047\">",
"      QRS prolongation and LBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise variables",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurohumoral activation and heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Signs of reduced tissue perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Low blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reduced glomerular filtration rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reduced myocardial blood flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREDICTIVE MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER PREDICTORS OF SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - S3 gallop and jugular venous pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Functional MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Heart rate variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Planar QRS-T angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Troponins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Low serum cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Weight loss and BMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Hypoalbuminemia and liver function abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Low plasma T3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Cytokines and other markers of inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Anabolic hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Albuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      mIBG imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Sleep disordered breathing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3477|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/28/34253\" title=\"figure 1\">",
"      NYHA class and survival HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/15/11517\" title=\"figure 2\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/28/10701\" title=\"figure 3\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/61/23517\" title=\"figure 4\">",
"      ACE inhibitor advanced HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/30/28141\" title=\"figure 5\">",
"      LVEF survival LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/15/35069\" title=\"figure 6\">",
"      Survival CHD LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/2/19501\" title=\"figure 7\">",
"      Transmitral flow outcome HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/14/44269\" title=\"figure 8\">",
"      Right ventricular EF outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/20/20813\" title=\"figure 9\">",
"      RV dilation and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/25/39325\" title=\"figure 10\">",
"      Tricuspid regurg outcome HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/44/25294\" title=\"figure 11\">",
"      Survival RVEF and PAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/32/24078\" title=\"figure 12\">",
"      LV mass LVEF outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/48/8973\" title=\"figure 13A\">",
"      Hormone levels in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/6/29805\" title=\"figure 13B\">",
"      Hyponatremia in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/38/43630\" title=\"figure 13C\">",
"      NE and survival ValHeFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/56/36750\" title=\"figure 13D\">",
"      BNP and survival ValHeFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15181\" title=\"figure 13E\">",
"      Big endothelin outcome HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/59/32701\" title=\"figure 14\">",
"      Heart rate variability HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/39/40572\" title=\"table 1\">",
"      Predictors of survival HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3477|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?31/45/32470\" title=\"waveform 1\">",
"      Doppler diastolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2617?source=related_link\">",
"      Approach to the patient with weight loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35223?source=related_link\">",
"      Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=related_link\">",
"      Cardiorenal syndrome: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/60/33735?source=related_link\">",
"      Echocardiographic evaluation of left ventricular diastolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4058?source=related_link\">",
"      Prognosis of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/15/23800?source=related_link\">",
"      Psychosocial factors in sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/25/14742?source=related_link\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24453?source=related_link\">",
"      Statin therapy in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_48_33547="Indications bone density";
var content_f32_48_33547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The National Osteoporosis Foundation indications for bone density testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Women aged 65 years and older and men age 70 and older, regardless of clinical risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Younger postmenopausal women and men age 50 to 70 about whom you have concern based on their clinical risk factor profile.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women in the menopausal transition if there is a specific risk factor associated with increased fracture risk, such as low body weight, prior low-trauma fracture, or high risk medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults who have a fracture after age 50.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults with a disease or condition (eg, rheumatoid arthritis) associated with low bone mass or bone loss.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults taking medication (eg, glucocorticoids, 5 mg or more daily for&nbsp;three or more months) associated with low bone mass or bone loss.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anyone being considered for pharmacologic osteoporosis therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anyone being treated for osteoporosis, to monitor treatment effect.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anyone not receiving therapy in whom evidence of bone loss would lead to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postmenopausal women discontinuing estrogen should be considered for bone density testing according to the indications listed above.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis. file://www.nof.org/professionals/NOF_Clinician's_Guide.htm (Accessed April 28, 2008).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33547=[""].join("\n");
var outline_f32_48_33547=null;
var title_f32_48_33548="Risk stratification";
var content_f32_48_33548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of death or severe morbidity during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardiac disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of cardiac complications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mortality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        <p>",
"         Small left-right shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus)",
"        </p>",
"        <p>",
"         Mild pulmonic/tricuspid valve abnormalities",
"        </p>",
"        <p>",
"         Corrected tetralogy of Fallot",
"        </p>",
"        <p>",
"         Bioprosthetic valve",
"        </p>",
"        <p>",
"         Repaired lesions without residual cardiac dysfunction",
"        </p>",
"        <p>",
"         Isolated mitral valve prolapse without significant regurgitation",
"        </p>",
"        <p>",
"         Bicuspid aortic valve without stenosis",
"        </p>",
"        <p>",
"         Valvular regurgitation with normal ventricular systolic function",
"        </p>",
"       </td>",
"       <td>",
"        Low risk",
"       </td>",
"       <td>",
"        &lt;1 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        <p>",
"         Mitral stenosis",
"        </p>",
"        <p>",
"         Large left-to-right shunt",
"        </p>",
"        <p>",
"         Mechanical prosthetic heart valve",
"        </p>",
"        <p>",
"         Severe pulmonic stenosis",
"        </p>",
"        <p>",
"         Aortic stenosis",
"        </p>",
"        <p>",
"         Uncorrected coarctation of aorta",
"        </p>",
"        <p>",
"         Uncorrected tetralogy of Fallot and other unrepaired cyanotic congenital heart disease",
"        </p>",
"        <p>",
"         Previous myocardial infarction",
"        </p>",
"        <p>",
"         Moderate to severe systemic ventricular dysfunction",
"        </p>",
"        <p>",
"         History of peripartum cardiomyopathy without residual dysfunction",
"        </p>",
"       </td>",
"       <td>",
"        Intermediate risk",
"       </td>",
"       <td>",
"        5-15 percent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        <p>",
"         Marfan syndrome with aortic or valvular involvement",
"        </p>",
"        <p>",
"         Severe pulmonary hypertension",
"        </p>",
"        <p>",
"         NYHA class III and IV symptoms",
"        </p>",
"        <p>",
"         Severe aortic stenosis",
"        </p>",
"        <p>",
"         History of peripartum cardiomyopathy with residual ventricular dysfunction",
"        </p>",
"       </td>",
"       <td>",
"        High risk",
"       </td>",
"       <td>",
"        25-50 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The above table represents a general guideline, but patient-specific factors must be taken into account. For example, some women with repaired Tetralogy of Fallot may have significant pulmonary regurgitation, which increases their risk of cardiac complications. In addition, effective anticoagulation can be difficult to maintain in pregnant women with mechanical prosthetic values, particularly older generation mitral valves, thus placing these women at high risk of bleeding or thrombotic complications.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: van Mook WN, Peeters L. Severe cardiac disease in pregnancy, part I: hemodynamic changes and complaints during pregnancy, and general management of cardiac disease in pregnancy. Curr Opin Crit Care 2005; 11:430. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33548=[""].join("\n");
var outline_f32_48_33548=null;
var title_f32_48_33549="Initiating Rx 12 and up";
var content_f32_48_33549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifying asthma severity and initiating treatment in youths greater than or equal to 12 years of age and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"3\">",
"        Components of severity",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Classification of asthma severity (&ge;12 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Intermittent",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"4\">",
"        Persistent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle3\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle3\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        <p>",
"         Impairment",
"        </p>",
"        <p>",
"         Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC:",
"        </p>",
"        <p>",
"         8 to 19 years 85 percent",
"        </p>",
"        <p>",
"         20 to 39 years 80 percent",
"        </p>",
"        <p>",
"         40 to 59 years 75 percent",
"        </p>",
"        <p>",
"         60 to 80 years 70 percent",
"        </p>",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        3 to 4x/month",
"       </td>",
"       <td>",
"        &gt;1x/week but not nightly",
"       </td>",
"       <td>",
"        Often 7x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week but not daily, and not more than 1x on any day",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Minor limitation",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung function",
"       </td>",
"       <td>",
"        <p>",
"         &bull; Normal FEV",
"         <sub>",
"          1",
"         </sub>",
"         between exacerbations",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC normal",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &ge;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC normal",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &gt;60 but &lt;80 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC reduced 5 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         &lt;60 percent predicted",
"        </p>",
"        <p>",
"         &bull; FEV",
"         <sub>",
"          1",
"         </sub>",
"         /FVC reduced &gt;5 percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Exacerbations requiring oral systemic glucocorticoids",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0 to 1/year (see footnote)",
"        </strong>",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Frequency and severity may fluctuate over time for patients in any severity category",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Relative annual risk of exacerbations may be related to FEV",
"         <sub>",
"          1",
"         </sub>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\" rowspan=\"3\">",
"        Recommended step for initiating treatment",
"       </td>",
"       <td rowspan=\"2\">",
"        Step 1",
"       </td>",
"       <td rowspan=\"2\">",
"        Step 2",
"       </td>",
"       <td>",
"        Step 3",
"       </td>",
"       <td>",
"        Step 4 or 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        And consider short course of oral systemic glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        In two to six weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Assessing severity and initiating treatment for patients who are not currently taking long-term control medications.",
"    </strong>",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. Level of severity is determined by assessment of both impairment and risk. Assess impairment domain by patient's/caregiver's recall of previous two to four weeks and spirometry. Assign severity to the most severe category in which any feature occurs. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma severity. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate greater underlying disease severity. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second; FVC: forced vital capacity; ICU: intensive care unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33549=[""].join("\n");
var outline_f32_48_33549=null;
var title_f32_48_33550="LVEF reversible doxo cardiotoxicity";
var content_f32_48_33550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Left ventricular ejection fraction with reversible doxorubicin cardiotoxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 345px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential measures of left ventricular ejection fraction (LVEF) in six patients in whom doxorubicin was discontinued after demonstration of moderate toxicity. The relation between LVEF and cumulative doxorubicin dose up to the time of moderate cardiotoxicity is shown on the left, and that between LVEF and time after cessation of therapy in the same patients is shown on the right. LVEF increased modestly in all six patients after discontinuation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Alexander, J, Dainiak, N, Berger, HJ, et al, N Engl J Med 1979; 300:278.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33550=[""].join("\n");
var outline_f32_48_33550=null;
var title_f32_48_33551="Nasopharyngeal airways";
var content_f32_48_33551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasopharyngeal airways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_48_33551=[""].join("\n");
var outline_f32_48_33551=null;
